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Introduction: Many human traits or complex diseases are known to result from the 
combined effect of genes, environmental factors, and interactions of them. Gene-by-
environment interactions (GxEs) may hold the key to further insights on the biology 
of disease and the development of better prediction models, particularly when genes 
interacting with modifiable environmental factors are investigated at a genome-wide 
level. Dyslipidemia and hypertension, one of the most prevalent chronic diseases for 
Koreans, are well-established risk factors for cardiovascular disease (CVD). Several 
studies on the complex diseases imply the possible roles of gene-by-obesity or gene-
by-lifestyle interactions on the risk of dyslipidemia or hypertension. Current genetic 
studies, including genome-wide association studies (GWASs), have identified more 
than 500 and 800 variants of lipids and blood pressure (BP) levels, respectively. Even 
though recent GWASs have successfully identified dozens of genetic markers related 
to plasma lipids or BP levels, the interaction structures are not well-known. Thus, we 
intended to search lipid-associated or BP-associated variants modifying the effect of 
lifestyle factors, such as cigarette smoking, alcohol consumption, and obesity, on the 
risk of dyslipidemia or hypertension at a genome-wide scale. 
 
Materials and Methods: A total of 18,025 individuals of Korean descent from four 
independent genome cohorts, a part of the Korean Genome and Epidemiology Study 
(KoGES), were included in this study. We determined dyslipidemia and hypertension 
by using the clinical cut-offs of high-risk CVD groups; lifestyle factors in this study 
were also defined based on the clinical thresholds. We conducted emerging analytical 
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models as possible to investigate gene-by-obesity and gene-by-lifestyle interactions 
on the risk of dyslipidemia and hypertension for Koreans; a total of 3,914,038 single-
nucleotide polymorphisms (SNPs) were examined for detecting GxEs. We replicated 
all the findings by using the independent Korean genome cohorts and estimated how 
much phenotypic variance or heritability was additionally explained by considering 
gene-by-obesity or gene-by-lifestyle interactions. These two independent studies on 
dyslipidemia and hypertension were further investigated by using the different scales 
of outcomes (continuous vs. dichotomous) to estimate whether the scale differences 
had affected the results from our previous genome-wide interaction scans (GWISs). 
 
Results: In GWISs for dyslipidemia, we identified and replicated about 20 gene-by-
obesity interactions attributable to novel genetic variants (SCN1A and SLC12A8) and 
lipid-associated variants (APOA5, BUD13, ZNF259, and HMGCR), which have been 
reported in previous studies. Genetic contributions, on the other hand, were markedly 
higher when several independent gene-by-obesity interactive SNPs were present for 
each pair of lipids and environmental factors. The gain of heritability was substantial 
for triglycerides (TGs) but mild for low-density lipoprotein cholesterol (LDL-C) and 
total cholesterol (Total-C); GxEs explained up to 18.7% of TG, 2.4% of LDL-C, and 
1.9% of Total-C heritability with waist-hip ratio (WHR). In GWISs for hypertension, 
we newly found and replicated 24 gene-by-lifestyle interactions attributable to novel 
variants (BRAP and SH2B3), BP-associated variants (ATP2B1), and genetic variants 
associated with alcohol consumption (ALDH2, CUX2, HECTD4 (C12orf51), MYL2, 
OAS3) and obesity (ST5). Genetic contributions increased with differences between 
GWAS-identified and total genetic impacts of 0.3-2.1% by considering the combined 
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effect of marginal genetic associations and interactions of the identified variants with 
lifestyle factors. In quantitative GWISs for lipids and BP levels, moreover, we found 
and replicated four genetic markers located on APOA5 and BUD13, which interacted 
with obesity and modified TG levels. All the findings were in linkage disequilibrium 
(LD) with rs1558860 located on BUD13, which reported in our previous GWISs for 
the risk of abnormal TG elevation, except for rs2041967 (r2=0.20). We also found a 
novel SNP located on TSPAN5 interacting with heavy drinking to modify SBP levels. 
 
Conclusions: Our findings suggest that some individuals are prone to develop lipid 
abnormalities or hypertension, even though they are categorized into normal or even 
into the low-risk group based on lifestyle factors, such as cigarette smoking, alcohol 
consumption, and obesity traits. Moreover, the ethnic diversities in the risk alleles of 
lipid or BP indices might explain the differential risk of dyslipidemia or hypertension 
between populations. These newly identified gene-by-obesity and gene-by-lifestyle 
interactions can be used to classify individuals into higher-risk or lower-risk groups 
of each complex trait and to personalize health guidelines for managing lipids or BP 
levels or lifestyle risk factors according to an individual’s genetic constitution. 
 
Keywords: Dyslipidemia; Hypertension; High Blood Pressure; Cigarette Smoking; 
Alcohol Consumption; Obesity; Gene-by-Environment Interaction (GxE); Genome-
Wide Interaction Scan (GWIS); Missing Heritability; Meta-Analysis; 
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1.1. Polygenic Inheritance 
Many human traits or diseases are known to be a consequence of the combined effect 
of genes, environmental factors, and interactions of them. These complex traits, also 
known as multifactorial or quantitative traits, do not simply follow Mendel’s laws of 
inheritance: the law of 1) uniformity, 2) segregation, and 3) independent assortment. 
The polygenic model (also termed the infinitesimal model) proposed by R.A. Fisher 
in 1918 can explain the continuous variation of such traits. It assumes that a variation 
in complex traits is influenced by several genes having a small effect on phenotypes, 
as well as by environmental factors. Despite the successful description in inheritance 
patterns, it remained unclear until the past decade how many genes or genetic factors 
would actually be significant for driving human complex traits or diseases. 
 
1.2. Genome-Wide Association Study 
A genome-wide association study (GWAS) is an approach for testing associations of 
genetic markers, called single-nucleotide polymorphisms (SNPs), with specific traits 
in the entire genome (1-3). The first GWAS using early versions of high-density SNP 
chips was reported in the early 2000s (4, 5). During the past ten years, GWASs have 
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led to many remarkable findings of human complex traits (6, 7); the GWAS Catalog, 
an online database compiling the results of GWASs, contains 7,796 publications and 
159,202 SNP-trait associations in October of 2019. The advent of GWASs and more 
lately next-generation sequencing (NGS) technologies, such as whole-exome (WES) 
and whole-genome sequencing (WGS), has provided opportunities to understand the 
genetic basis of human complex traits or diseases in detail. 
 
1.3. Missing Heritability 
Heritability, the ratio of genetic components to total phenotypic variance, is a major 
population parameter measuring the contribution of genetic factors to complex traits 
(8). It is formally defined as the proportion of total phenotypic variation attributable 
to additive or total genetic variances: the narrow-sense heritability (h2) or the broad-
sense heritability (H2), respectively (8, 9). Despite success in the findings of dozens 
of SNPs associated with complex traits, a substantial amount of heritability remains 
unclear; the identified SNPs only explain a fraction of the predicted heritability. This 
mystery has been termed the missing heritability (10, 11). 
 
There are several explanations and potential sources of the missing heritability: 1) a 
number of variants having moderate or smaller effects than GWAS-identified SNPs, 
2) genetic variants of low minor allele frequency (MAF) or rare variants 3) gene-by-
gene interactions (GxGs), 4) structural or copy number variations (CNVs) including 
insertions and deletions, and 5) epigenetic alterations, such as deoxyribonucleic acid 
(DNA) methylations and histone modifications (10-13). Interactions between genes 
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and environmental factors are also suggested to be the potential source of the missing 
heritability (12, 13). 
 
2. Gene-by-Environment Interaction 
 
2.1. Definition 
In epidemiology, the term interaction is used to describe a phenomenon in which two 
or more factors change the other’s effect on a given outcome; it is also known as the 
effect modification. An interaction occurs when 1) the first factor’s effect on a given 
outcome is not homogeneous in subgroups stratified by the second risk factor, and 2) 
the observed joint effect of the factors differs from the expected joint effect based on 
their independent effects. Similarly, the term gene-by-environment interaction (GxE) 
is broadly defined as the joint effect of genes with environmental factors that are not 
explained by their marginal effects separately (14, 15). 
 
2.2. Genome-Wide Interaction Scan 
Current GxE studies have applied a candidate-gene approach to detect the interaction 
of genes with environmental factors. They have focused on a candidate region, which 
was localized based on prior information, usually consulted from GWASs estimating 
effects on marginal genetic associations. Candidate GxE studies tend to provide more 
power for testing interactions if the assumption about candidate-genes is appropriate; 
these studies, however, are incapable of finding novel genes independent from prior 
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information (16). A genome-wide interaction scan (GWIS), by contrast, investigates 
the entire genome to find interactions of genetic loci with weak or moderate marginal 
genetic effects as well as strong marginal effects. GWISs can pinpoint genes without 
any prior information; studies using the entire genome, such as GWISs and GWASs, 
are labeled as hypothesis-free or hypothesis-generating methods (17, 18). Genome-
wide approaches, however, have low statistical power due to the number of analyses 
performed independently (19, 20). GWISs focus on the estimate of effect differences 
between subgroups stratified by each gene and environmental factor, not the genetic 
effects on marginal associations mainly estimated in GWASs. 
 
2.3. Reasons and New Opportunities 
There are many incentives to investigate the interaction structure between genes and 
environmental factors: 1) providing insights into the biology of human complex traits 
or diseases, 2) developing better prognostic or prediction models to manage diseases, 
3) detecting high-risk groups in a given population and providing personalized health 
guidelines for them, and 4) allowing new opportunities for prevention and treatment 
of diseases (21-23). Moreover, the missing heritability may be explained additionally 
by the modifying effects of genetic factors attributable to GxEs. 
 
With available high-volume genetic data, such as NGS and multi-omics data, a study 
of GxEs has been a focus of genetic and epidemiological researches for several years. 
There are several successful findings from researches on GxEs: especially studies of 
metabolism genes and pathways, functional approaches, and model systems (21-24). 
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There are ongoing discussions about the incorporation of biological knowledge into 
the emerging GxE analyses; the use of gene-based, pathway-based, and multi-omics 
approaches may result in the identification of novel disease susceptibility loci, which 
contribute to the heritability (15, 24). 
 
2.4. Current Challenges 
Even though these successful studies have motivated researchers to find and describe 
how the interplay between genes and environmental factors influences complex traits 
or diseases, most of the studies have focused on only a few candidate-genes. Only a 
few studies on GxEs have been conducted to scan the entire genome to detect genetic 
loci interacting with environmental factors. It is mainly attributable to the limitations 
of GxE testing: 1) the inherently low statistical power, 2) the complexity of assessing 
environmental factors, 3) measurement errors, 4) restricted variations in both genetic 
and environmental factors, 5) the scale dependence in definition of interactions, and 
6) the lack of functional data on genetic variants (22, 25-29). On the other hand, new 
approaches, study designs, and statistical methods have been suggested to overcome 




3.1. Clinical Definition 
Dyslipidemia indicates an abnormal state of one or more lipid levels in the blood. It 
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is usually determined by using the following lipid profiles: elevated total cholesterol 
(Total-C) or low-density lipoprotein (LDL-C) or triglyceride (TG) or reduced high-
density lipoprotein cholesterol (HDL-C). Clinical cut-off points of each lipid profile, 
suggested by the National Cholesterol Education Program (NCEP), for dyslipidemia 
are as follows (32): 1) Total-C over 6.21 mmol/L or 2) HDL-C less than 1.03 mmol/L 
for males or less than 1.29 mmol/L for females or 3) LDL-C over 4.14 mmol/L or 4) 
TG over 2.26 mmol/L (Supplemental Table S1). 
 
3.2. Epidemiological Studies 
Dyslipidemia is a well-established risk factor for cardiovascular disease (CVD); the 
associations between lipid abnormalities and CVD risk are supported robustly by the 
accumulated findings from large-scale epidemiological studies (33-37). Even though 
there is an ongoing debate over the causative role for HDL-C in the risk of CVD (38), 
abnormalities in plasma levels of HDL-C and Total-C remain unimpeachable clinical 
predictors in the assessment of CVD risk (33, 36, 39, 40). Lowering LDL-C by using 
lipid-lowering drugs, such as statins, on the other hand, has become a key treatment 
for primary prevention of CVD in the last few decades (37, 41). TG-rich lipoproteins 
and their remnants have been reported as contributors to the remaining CVD risk in 
recent Mendelian randomization studies (34, 35, 42-44). 
 
3.3. Genetic Studies 
Blood lipids are known to be heritable and modifiable (45, 46); many genetic studies 
and meta-analyses have been performed to find out lipid-associated genes to develop 
7 
 
new therapies for CVD management and prevention (47-51). GWASs have identified 
more than 500 loci influencing plasma lipid levels in European ancestry cohorts (52-
62). The total variance explained by these loci in the Framingham Heart Study (FHS) 
was about 15.0% for quantitative Total-C levels, 13.7% for HDL-C levels, 14.6% for 
LDL-C levels, and 11.7% for TG levels, corresponding to 25-30% of the heritability 
of each lipid trait (52-54). 
 
3.4. Gene-by-Obesity Interaction Studies 
Previous GWASs on lipid profiles have been successful in terms of both the richness 
of robustly replicated loci and the genetic variances explained by these variants, but 
the current list of loci in the GWAS Catalog is based on marginal association models 
assuming a lack of genetic interactions, such as GxEs and GxGs. However, the ethnic 
differences in abnormal lipid profiles reactive to obesity suggest that the interaction 
between genetic background and obesity traits may play a specific role in regulating 
lipid concentrations (63). Compared with non-Hispanic whites, for example, African 
Americans have a lower prevalence of dyslipidemia despite a higher obesity risk (63, 
64). Conversely, despite similar or leaner body compositions than Caucasians of the 
same age and sex, the prevalence of dyslipidemia is increased in Asians (63, 65, 66), 
particularly those of Korean descent (63, 67, 68). 
 
A growing body of evidence from candidate-gene studies also supports the presence 
of gene-by-obesity interactions in lipid abnormalities; the effects of lipid-associated 
loci are modified according to obesity indices, such as body mass index (BMI), waist 
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circumference (WC), and waist-hip ratio (WHR) (69-73). Only a few studies, on the 
other hand, have been performed at a genome-wide scale to identify genetic variants 
influencing lipid levels based on obesity status. Moreover, these studies were carried 
out using a genetic risk score (GRS) or a two-step approach rather than an exhaustive 
method (74-77). Current findings of gene-by-obesity interactions on abnormal lipid 
profiles are also predominantly based on Europeans (69-71, 73-77); the GxE effects 
could have been underestimated if non-Caucasians are more susceptible to genes of 




4.1. Clinical Definition 
Hypertension, also known as high blood pressure (HBP), is a chronic condition with 
a persistent abnormal elevation of the blood pressure (BP) in the arteries. It is usually 
determined by elevated levels of systolic BP (SBP) or diastolic BP (DBP). Recently, 
the American Heart Association (AHA) has suggested two stages of hypertension in 
their guidelines for prevention, detection, evaluation, and management of HBP (78): 
stage 1 (HBP-S1; 130≤SBP<140 mmHg or 80≤DBP<90 mmHg) and stage 2 (HBP-
S2; SBP≥140 mmHg or DBP≥90 mmHg) (Supplemental Table S1). 
 
4.2. Epidemiological Studies 
Hypertension, also referred to as HBP, is the most common and modifiable risk factor 
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for CVD, mortality, and disability around the world (79). Even within normal ranges, 
elevated levels of SBP or DBP have a graded and continuous influence on CVD risk 
(80). Increased SBP has been reported to be associated with the highest global burden 
of disease (GBD) among risk factors in 2015. It is even higher than the global burden 
of cigarette smoking or obesity (79); GBD attributable to HBP has been described in 
detail for 2005, 2010, and 2015 (79, 81, 82). Moreover, the benefit of reducing levels 
of BP for management of CVD has already been proven in clinical trials, large-scale 
epidemiological studies, meta-analyses, and systematic reviews (83). 
 
The mortality attributable to CVD is remarkably decreasing in the United States and 
Canada (84, 85); mortality due to CVD for Koreans, on the other hand, has continued 
to increase according to the Korean Statistical Information Service (KOSIS). These 
trends in CVD-related mortality seem to depend on whether major CVD risk factors, 
such as hypertension and dyslipidemia, are well controlled or not (85, 86). The recent 
decrease in CVD-related mortality in Western countries, for example, is mainly due 
to the declining prevalence of CVD risk factors (85). The prevalence of hypertension 
and dyslipidemia among middle-aged Koreans, by contrast, has been even increasing 
or remaining constant (87); hypertension is the most prevalent (25.8%) health-related 
condition, followed by dyslipidemia (16.6%) (88). 
 
4.3. Genetic Studies 
Evidence from genetic studies, such as GWASs, exome-wide association studies, and 
meta-analyses in various ethnic groups, has found several genetic variants associated 
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with quantitative BP and hypertension (89-93). In 2009, 13 independent genetic loci 
associated with BP and HBP were reported from two European consortia: the Global 
Blood Pressure Genetics (Global BPgen) and Cohorts for Heart and Aging Research 
in Genome Epidemiology (CHARGE) (89, 90). On the other hand, the Asian Genetic 
Epidemiology Network Blood Pressure (AGEN-BP) group newly reported five loci 
associated with SBP and DBP among East Asian ancestry groups (92). 
 
Recent GWASs have identified more than 800 loci associated with BP traits, such as 
SBP, DBP, and pulse pressure (PP), among one million people of European ancestry 
drawn from the United Kingdom Biobank (UKB) (94, 95). The heritability of BP is 
moderate; it is about 40% across twin and family-based studies (96). The heritability 
attributable to common (MAF>0.10) variants for SBP and DBP in European ancestry 
is 20% and 27%, respectively. For African ancestry, on the other hand, the heritability 
due to common SNPs for SBP and DBP is 50% and 39%; the estimates are based on 
data from the Atherosclerosis Risk in Communities (ARIC) population-based cohort 
study (97). Only a small fraction, less than 5%, of the total variance is attributable to 
GWAS-identified BP SNPs (98). 
 
4.4. Gene-by-Lifestyle Interaction Studies 
Several GxE studies have already been proposed to elucidate the genetic architecture 
of hypertension (99-104). Two novel BP loci interacting with cigarette smoking have 
been found in African American individuals, according to the Hypertension Genetic 
Epidemiology Network (HyperGEN) study and the Genetic Epidemiology Network 
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of Arteriopathy (GENOA) study (103). Seven significant and 21 suggestive BP SNPs, 
including genetic variants interacting with cigarette smoking, have been found from 
the FHS SNP Health Association Resource (SHARe) (101); they have also identified 
one significant and 20 suggestive BP loci interacting with alcohol consumption (100). 
Chinese research on BP, on the other hand, has reported ten lipid-associated variants 
interacting with overweight or obesity to modify effects on BP (99). However, most 
results from these GxE studies on BP are based on candidate-gene or two degrees of 
freedom (2-df) tests. There are relatively fewer GxE studies on HBP, focusing on the 
interplay between genes and lifestyle factors at a genome-wide set of variants. 
 
5. Aims of the Thesis 
 
The main purpose of this thesis is to identify the interaction of genetic susceptibility 
loci with modifiable environmental factors and suggest the general framework to test 
the interactions at a genome-wide scale. We investigated genetic markers interacting 
with lifestyle factors to modify the risk of dyslipidemia and hypertension, estimated 
additional heritability attributable to the variants, and compared results between GxE 
analyses using dichotomous and quantitative outcomes. For this end, we carried out 
two independent studies applied emerging statistical methods for testing GxE in the 
entire genome: 1) a genome-wide search for gene-by-obesity interactions on the risk 
of dyslipidemia and 2) a genome-wide search for genetic interactions with cigarette 
smoking, alcohol consumption, and obesity, so-called lifestyle factors, on the risk of 
hypertension. These two independent studies were also further investigated by using 
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a quantitative scale of the phenotypes: 3) a genome-wide search for gene-by-lifestyle 
interactions on quantitative lipid and BP levels. 
 
In the first study, we hypothesized that some genetic variants modified the effects of 
obesity on the risk of dyslipidemia and assumed that these genetic loci might include 
both novel and known genes with different reactive effect sizes. We also proposed a 
hypothesis that the novel gene-by-obesity interactions underlying lipid traits explain 
more of the total and genetic variances of each lipid parameter than do the SNPs with 
only marginal effects. In the second study, we investigated the interactions of genetic 
markers with lifestyle factors, such as cigarette smoking, alcohol consumption, and 
obesity, on the risk of hypertension. We also proposed a hypothesis that the total and 
genetic variances of HBP are additionally explained by the newly detected gene-by-
lifestyle interactions underlying HBP parameters. In the third study, we hypothesized 
that there was some novel and known genes modifying the effects of lifestyle factors 
on quantitative lipid and BP levels. We also expected that the identified variants were 
replicated with our previous findings and had consistent directions of genetic effects 
regardless of the scale of outcome variables. 
 
In general, a genome-wide analysis for testing GxEs is believed to suffer from weak 
statistical power rather than type 1 errors or false-positive findings (105). Partly due 
to this issue, replicating new findings has not been widely accepted as a prerequisite 
for reporting GxEs. However, we believe replications in GxE studies are as important 
as in GWASs. For identifying and replicating gene-by-obesity and gene-by-lifestyle 
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interactions at a genome-wide scale, we carried out emerging GxE methods by using 
four independent Korean genome cohorts. The identification of genetic interactions 
with potentially modifiable risk factors will facilitate the knowledge-based approach 
























1.1. Low Statistical Power 
As outlined previously, low statistical power is the inherent limitation of GxE studies 
on complex traits or diseases (22). Compared with a GWAS focusing on the marginal 
or direct association test, the analysis on GxEs requires much larger sample sizes to 
find interactions between genes and environmental factors. Furthermore, the sample 
size requirement is further inflated to overcome the problem of multiple comparisons 
for testing interactions at a genome-wide scale (15, 105). Therefore, most analytical 
methods have emerged to improve the power of testing GxEs (30, 31). 
 
Each analytical GxE model, on the other hand, provides differential statistical power 
of detecting interactions between genes and environmental factors, mainly according 
to marginal genetic and GxE effects (30). If we have any prior information about the 
effect sizes, we will choose a specific test offering substantially greater power to test 
GxEs at a genome-wide scale. Unfortunately, it is hard to know any prior information 
about the marginal and interactive effects of each locus. As type 1 error rates or false-
positive findings are generally considered to be less problematic than underpowered 
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findings, it is recommended to use multiple analytical GxE models as possible (105). 
Further verification can be done by replications or stratified analyses for a candidate 
region localized by previous GxE analyses. 
 
1.2. Overview of Exhaustive Scans 
There are several analytical methods for testing interactions at a genome-wide scale: 
ten different approaches for this GWIS (30). GWISs can be classified into two main 
test types: 1) an exhaustive scan and 2) a two-step method, including screening (step-
1) and hypothesis testing (step-2). Exhaustive scans, such as case-control (CC), case-
only (CO) (106), and empirical Bayesian (EB) approaches (107), are direct one-step 
methods. A CC approach, for example, tests an interaction term of a standard logistic 
regression model; it estimates the effect differences between subgroups stratified by 
each genetic and environmental factor (30). A CO approach estimates environment-
gene correlation (EG) in the affected individuals; it provides greater statistical power 
than a CC method if genetic and environmental factors are independent in the source 
population (106, 108). An EB method integrates the results from a CC test with those 
of a CO test; it also provides greater statistical power than a CC approach (107, 109). 
 
1.3. Overview of Two-Step Methods 
Two-step methods, on the other hand, consist of a screening (step-1) and hypothesis 
testing (step-2). All the two-step approaches require a disease-gene association (DG) 
or EG information in step-1 to screen candidate SNPs interacting with environmental 
factors (30). There are various two-step approaches to identify GxE loci: 1) screening 
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with DG and testing with EB (DG1), 2) DG in step-1 and CC in step-2 (DG2) (110), 
3) EG in step-1 and CC in step-2 (EG2) (111), 4) a hybrid (H2) test (105), 5) Cocktail 
I (CT1), 6) Cocktail II (CT2) (112), and 7) combining both DG and EG in step-1 and 
CC in step-2 (EDGxE) (30). H2, CT1, CT2, and EDGxE methods require the results 
from DG and EG tests to screen candidate loci in step-1; a H2 test uses these tests in 
parallel, CT1 and CT2 tests adopt the information flexibly depending on the p-values 
of each DG and EG test, and an EDGxE method combines the results of DG and EG 
tests to generate new screening statistics. For step-2, H2 and EDGxE methods reflect 
the results of CC tests; CT1 and CT2 methods use an EB test if step-1 is based on a 
DG test and adopt a CC test if an EG test is used for a screening step (30). Analytical 
approaches, such as exhaustive scans and two-step methods, could be categorized by 
1) the assumption of independence between genetic and environmental factors in the 
source population, 2) methods for screening (step-1), and 3) methods for hypothesis 
testing (step-2) (Supplemental Figure S1). 
 
2. Exhaustive Scans 
 
2.1. Case-Control Analysis 
In a CC study consisting of N participants, we define Di (i=1, 2, ..., N) as an indicator 
of disease and Ei (i=1, 2, ..., N) as an environmental factor. Each SNP will be denoted 
Gi (i=1, 2, ..., N), which are usually coded as 0, 1, or 2 for genotype AA (two common 
alleles), Aa (one common allele and one minor allele), or aa (two minor alleles). For 
a GWAS, the marginal genetic effect on disease is estimated by the genetic odds ratio 
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(ORG), which can be obtained as the exponential of λG from the following statistical 
model: logit(Pr(Di=1|Gi))=λ0+λGGi. This logistic regression model can be augmented 
to test GxEs: logit(Pr(Di=1|Gi))=β0+βGGi+βEEi+βGxEGixEi. In this equation, the GxE 
effect on disease status is measured by the interactive odds ratio (ORGxE), which can 
be obtained as the exponential of βGxE from the augmented logistic regression model. 
We denote the approach using the augmented model as the CC analysis (30). 
 
2.2. Case-Only Analysis 
A standard CC analysis generally has low statistical power of detecting GxEs; a CO 
analysis can provide substantially greater power if genetic and environmental factors 
are independent in the source population (106, 108). A CO method estimates EG, the 
correlation between environmental factors and each SNP, in the affected individuals. 
The GxE effect on disease status is consistently estimated by the odds ratio (OR) for 
the genetic term, which can be obtained as the exponential of γGxE from the following 
logistic regression model: logit(Pr(Ei=1|Gi,Di=1))=γ0+γGxEGi. We denote the analysis 
using this equation as the CO analysis (30, 106, 108). 
 
2.3. Bayesian Approach 
Even though a CO analysis provides substantially greater power than a standard CC 
analysis, type 1 errors or false-positive rates of a CO test can be inflated unacceptably 
if the baseline assumption of independence between genes and environmental factors 
is violated (30, 106, 108). Bayesian approaches, such as an EB analysis and a Bayes 
model averaging (BMA) method (107, 109), have emerged to provide enough power 
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of testing GxEs without the potential inflation of type 1 errors or false-positive rates 
(30). EB and BMA methods integrate the estimated GxE effects from a CC test with 
those of a CO test; these Bayesian approaches reflect a measure of uncertainty about 
the baseline assumption of independence between genetic and environmental factors 
(107, 109, 113). Although EB and BMA methods can improve power to detect GxEs, 
these analyses can also induce type 1 errors or false-positive findings in the presence 
of correlation between genetic and environmental factors (105, 114). 
 
3. Two-Step Methods 
 
3.1. Hybrid Method 
Two-step approaches have suggested providing substantial power of detecting GxEs 
while preserving acceptable type 1 errors or false-positive rates (105, 110, 111). Any 
of the two-step methods require independence between screening (step-1) and testing 
(step-2) statistics (115). DG1 and DG2 tests use statistics for the marginal association 
of each variant to screen candidate SNPs in step-1. They conduct an EB or a CC test 
in step-2, respectively; the number of candidate SNPs screened in step-1 is reflected 
in Bonferroni correction (110). A DG1 method is known to be more powerful than a 
DG2 method (112). DG1 and DG2 methods satisfy the assumption of independence 
between screening and hypothesis testing statistics. 
 
An EG2 approach, on the other hand, defined screening statistics as SEG, the statistics 
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from EG correlation tests of each variant. The following logistic regression model is 
used to test the EG correlation: logit(Pr(Ei=1|Gi))=δ0+δGGi. For an EG2 approach, a 
CC analysis is conducted for hypothesis testing in step-2; the significant level is also 
adjusted for Bonferroni correction (111). A H2 methods uses SDG and SEG in parallel 
for screening candidate SNPs in step-1 and tests GxEs of each SNP in step-2 by using 
a standard CC test; the number of combined SNPs passed DG or EG screening steps 
is reflected in Bonferroni correction (105). 
 
3.2. Cocktail Approach 
CT1 and CT2 approaches also use the DG and EG results in parallel. A CT1 approach 
adopts different statistics for screening in step-1, according to the estimated p-values: 
1) SCT=SDG if the p-value of SDG is less than a given threshold, usually 0.001, and 2) 
SCT=SEG otherwise. A CT2 approach, on the other hand, defines SCT as the maximum 
value of SDG and SEG: 1) SCT=SDG if the p-value of SDG is less than the p-value of SEG 
and 2) SCT=SEG if the p-value of SEG is less than the p-value of SDG. For the hypothesis 
testing in step-2, both cocktail methods use SEB if SCT=SDG and SCC if SCT=SEG (112). 
 
3.3. EDGxE Method 
The emerging two-step methods, such as DG1, DG2, EG2, and cocktail approaches, 
use both DG and EG information for screening candidate SNPs in step-1; the use of 
both SDG and SEG enhances the statistical power of detecting GxEs at a genome-wide 
scale (30, 110, 111). These two-step methods, however, do not consider SDG and SEG 
simultaneously; we need to select one or the other statistic of a given SNP in step-1. 
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An EDGxE method differs from the previous two-step methods in that this approach 
simultaneously considers both SDG and SEG to prioritize SNPs for hypothesis testing; 
it defines screening statistics, SEDGxE, as the sum of SDG and SEG. An EDGxE method 
adopts GxE statistics, SCC, estimated by using a standard CC analysis for hypothesis 
testing in step-2 (30); the screening (step-1) and hypothesis testing (step-2) statistics 
are also independent of each other. 
 
4. Type 1 Error and Statistical Power 
 
4.1. Type 1 Error 
The suggested analytical models for testing GxEs, such as CC, CO, EB, and several 
two-step methods, achieved permissible type 1 error rates around the nominal alpha 
of 0.05 in simulation studies with multiple scenarios (30, 116). In simulation studies 
with 3,500 cases and 3,500 controls, so-called CC settings, false-positive rates were 
estimated by varying the number of disease susceptibility loci with DG associations 
or EG correlations (Reference Table R1). Exhaustive tests using CC and EB, and all 
two-step approaches, as expected, achieved the nominal type 1 error or false-positive 
rates regardless of the presence of SNPs with DG associations or EG correlations in 
the source population. CO analyses, by contrast, had extremely high (>0.999) false-
positive rates if any variants had EG correlations in the source population (30). These 
trends of type 1 error rates were constant in population settings with 1,000 cases and 
1,000 to 9,000 controls (116). The independence between genes and exposures need 
to be considered to avoid possible false-positive findings from CO analyses. 
21 
 
4.2. Statistical Power 
The emerging analytical approaches, on the other hand, show a differential power to 
test GxEs in simulation studies with multiple scenarios (30, 116). In the CC settings, 
statistical power was investigated by varying the magnitude of marginal associations 
and interactions, the frequency of genetic and environmental factors, and the number 
of SNPs having DG or EG correlations (Reference Table R2 and Figure R1). If there 
are no significant EG correlations in the source population, the CO analysis provides 
substantially greater power of testing GxEs than the standard CC analysis (106, 108). 
The EDGxE method considering both SDG and SEG to prioritize SNPs for hypothesis 
testing provides the highest power than the other approaches in most scenarios (30). 
 
In the population settings, on the other hand, the true-positive rate or statistical power 
was simulated by varying the prevalence of disease and exposure, and the magnitude 
of interactions (Reference Figure R2) (116). Similar to the assessed power in the CC 
settings, the CO test provides higher power to detect GxEs than the other exhaustive 
scans, such as CC and EB, regardless of the prevalence of disease and exposure, and 
the ORGxE. Two-step approaches, on the other hand, show substantially greater true-
positive rates than exhaustive scans. In most scenarios, the H2 achieves a higher true-
positive rate; the modified H2 method (116, 117), which considers both SDG and SEG 
in the screening step as like as the EDGxE, offers the highest power. In general, it is 
recommended to use multiple analytical models as possible to test interactions (105), 
because it is hard to have any prior information about marginal associations or GxEs 
at genome-wide scales. We can further verify the findings by replications or stratified 




A Genome-Wide Search for 
Gene-by-Obesity Interaction Loci of Dyslipidemia 
 
1. Materials and Methods 
 
1.1. Participants 
A total of 18,025 individuals from four independent Korean cohorts with a genome-
wide set of SNPs were included in this study on dyslipidemia: 4,637 individuals from 
the Ansan cohort, 4,205 individuals from the Ansung cohort, 3,700 individuals from 
the urban cohort, and 5,483 individuals from the rural cohort. Participants who have 
suffered cancer or diabetes were excluded from this study; people taking any kind of 
lipid-lowering drug were considered as dyslipidemia patients (Supplemental Figure 
S2). Table 1 shows the baseline characteristics of each Korean cohort (Supplemental 
Table S2 and S3); a total of 16,014 individuals were included in this study. 
 
Participants in the reference set, the Ansan and Ansung cohorts, were aged about 40-
69 years and recruited from industrialized suburban and rural regions of the Republic 
of Korea. Participants in the replication set, including the urban and rural cohorts, on 
the other hand, were aged over 40 years and recruited from urban medical institutions 
and rural areas of Korea: Gangwha, Goryeong, Namwon, Pyeongchang, Wonju, and 
Yangpyeong. These cohorts are part of the Korean Genome and Epidemiology Study 
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(KoGES), an ongoing population-based cohort study initiated in 2001 to understand 
chronic diseases among Koreans. The research protocols and data in this study were 
approved by the Institutional Review Board (IRB) of Seoul National University (IRB 
number: E1805-003-001) and followed the Declaration of Helsinki principles. 
 
1.2. Measurements 
Data on health status, health-related behaviors, and medical and medication histories 
were collected through a standardized questionnaire. Trained experts at each clinical 
center conducted anthropometric measurements, specimen collection, and laboratory 
tests. All participants provided informed consent for the baseline data and specimens; 
more detailed protocols were described in previous reports (118, 119). Total-C, 
HDL-C, and TG were measured using traditional enzymatic methods in the blood 
samples drawn after an 8-hour fast. For individuals with TG under 4.52 mmol/L, 
LDL-C was calculated using the Friedewald’s formula (120); we determined 
remnant cholesterol (Remnant-C) as the level of Total-C minus HDL-C minus LDL-
C (42, 44). We used directly measured height, weight, WC, and hip circumference 
(HC) to calculate BMI and WHR, the obesity traits. 
 
1.3. Phenotypes 
We defined dyslipidemia based on clinical cut-offs of high-risk CVD groups reported 
in the NCEP guides (32): 1) Total-C over 6.21 mmol/L, 2) LDL-C over 4.14 mmol/L, 
3) TG over 2.26 mmol/L, 4) the lowest quintile of HDL-C, and 5) the highest quintile 
of Remnant-C. Individuals who have taken any kind of lipid-lowering drug, such as 
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statins, were considered as dyslipidemia patients in statistical analyses. Obesity traits 
were defined by using clinical cut-offs suggested by the National Institutes of Health 
(NIH) and the Korean Society for the Study of Obesity (KSSO) (121, 122). We used 
a total of six obesity indices: 1) overweight class 1 (BMI≥23.0 kg/m2), 2) overweight 
class 2 (BMI≥25.0 kg/m2), 3) obesity (BMI≥30.0 kg/m2), 4) abdominal obesity class 
1 (WC>90 cm for males, 80 cm for females), 5) abdominal obesity class 2 (WC>102 
cm for males, 88 cm for females), and 6) abdominal obesity defined as a WHR above 
0.90 for males and 0.85 for females (Supplemental Table S1). 
 
1.4. Genotype Information 
We used a genome-wide set of variants genotyped by using the following dense SNP 
microarrays: the Affymetrix Genome-Wide Human SNP Array 5.0 for the Ansan and 
Ansung cohorts, the Affymetrix Genome-Wide Human SNP Array 6.0 for the urban 
cohort and a part of the rural cohort (n=1,816), and the Illumina HumanOmni1-Quad 
BeadChip for the rest part of the rural cohort (n=3,667). Any variant violating Hardy-
Weinberg equilibrium (p-value<1x10-6), with genotype call rates below 95%, or with 
MAF values below 0.01 were excluded. After quality control, the remaining markers 
were imputed by using the 1000 Genomes Project’s haplotypes phase I in NCBI 
build 37 (GRCh37/hg19) of the Asian references. We used SHAPEIT2 and 
IMPUTE2 for the haplotype phasing and imputation processes, respectively (123, 
124). Only SNPs with quality scores higher than 0.6 were retained, yielding 
4,780,608 variants for the reference set and 5,729,661 variants for the replication set. 
After comparing each set, a total of 3,914,038 overlapping variants were selected as 
the final genetic markers. 
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1.5. Statistical Analyses 
The risk of dyslipidemia was adjusted for age, age2, sex, and each obesity trait, such 
as obesity and abdominal obesity, one by one; the logarithm of OR was corrected by 
using a logit model. Before GWISs, we conducted marginal DG and EG tests for the 
3.9 million SNPs; genetic markers associated with both lipids and obesity traits were 
excluded to reduce potential pleiotropy (p-value<1x10-3). Exhaustive scans, such as 
CC, CO (106), and EB methods (107), are direct one-step approaches; a CC analysis 
tests the null hypothesis βGxE=0 using a standard GxE model, a CO analysis tests the 
EG in affected individuals, and an EB analysis integrates the estimated effects from 
a CC test with those of a CO test. 
 
Two-step methods, on the other hand, comprise screening and hypothesis testing. We 
carried out emerging two-step methods in parallel: DG1, DG2 (110), EG2 (111), H2 
(105), CT1, CT2 (112), and EDGxE methods (30). H2, CT1, CT2, and EDGxE adopt 
both DG and EG information to screen genetic markers in step-1; H2 uses these tests 
in parallel, CT1 and CT2 apply the information flexibly depending on the p-value of 
DG and EG tests, and an EDGxE combines statistics of DG and EG to generate new 
screening statistics. For hypothesis testing in step-2, H2 and EDGxE adopt the results 
from a CC test; CT1 and CT2 apply an EB when screening is based on a DG test and 
adopt a CC if they use an EG to screen genetic markers. 
 
After finding novel GxE variants, we applied the standard genome-wide significance 
level (p-value<5x10-8) for exhaustive scans. We determined a threshold of screening 
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as 1x10-4 for the first step of DG1, DG2, EG2, and H2 methods; for step-2, the subset 
of SNPs passing step-1 was tested at a more liberal cut-off point (0.05 divided by the 
number of screened SNPs) (105). We adopted weighted hypothesis testing in step-2 
of CT1, CT2, and EDGxE approaches rather than testing only SNPs passing step-1; 
stepwise penalties due to the marginal p-value were applied for each variant in step-
2 (125). We removed one of a pair of the identified variants if linkage disequilibrium 
(LD) was greater than 0.5, which means a variance inflation factor (VIF) was greater 
than 2, for informed LD pruning (LD clumping). We identified novel GxE loci using 
the reference set consisting of the Ansan and Ansung cohorts; all identified GxE loci 
were reconfirmed using the replication set composed of the urban and rural cohorts. 
We considered the effect size, magnitude of standard error, p-value, and the direction 
of effect to estimate the final result of meta-analyses. We used PLINK (126), METAL 
(127), and R in the analyses. 
 
1.6. Methods of Evaluating Impacts 
We estimated genetic variances attributable to the genetic susceptibility SNPs using 
the simplified equation 2p(1-p)[log(OR)]2, where p is MAF of the variant and OR is 
the estimated OR from the logistic regression model for marginal associations (128). 
The genetic contribution of each variant was estimated using the simplified equation 
2p(1-p)[log(ORG)]2/VP+2ep[(1-p)+2p(e-1)2][log(ORGxE)]2/VP. In this equation, VP is 
the phenotypic variance, e is the prevalence of an environmental factor, and ORG or 
ORGxE are estimated ORs due to main SNP or gene-by-obesity interactions from the 
logistic regression model for GxEs. We used GenABEL, the R package for genome-
wide association analyses (129), to estimate the heritability of dyslipidemia from the 
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Healthy Twin Study, a family-based cohort study in Korea (Supplemental Table S3.e) 
(130, 131). GCTA, the analysis tool for genome-wide complex traits (132), was also 
used to estimate the SNP-based heritability attributable to all genetic markers on the 
SNP microarray. To transform the estimates of phenotypic variance explained on the 
observed scale to the estimations on the underlying scale, we assessed the prevalence 
of dyslipidemia from the Korean National Health and Nutrition Examination Survey 
(KNHANES) (133); the prevalence of abnormal Total-C, HDL-C, LDL-C, TG, and 




2.1. Characteristics of the Study Populations 
Table 1 shows the baseline characteristics of the participants in each Korean genome 
cohort. We observed age, sex, obesity-related measurements, and plasma lipid levels 
adjusted for age, age2, and sex; all features were stratified into subgroups for obesity 
traits based on BMI, WC, and WHR (Supplemental Table S2 and S3). We examined 
the adjusted lipids to assess the trends of lipids in each obesity and abdominal obesity 
subgroup. As expected, the adjusted plasma lipid levels were significantly worsened 
as a degree of obesity or abdominal obesity status increased in the combined Korean 





2.2. Identification of Gene-by-Obesity Interactive Loci 
We identified 55 SNPs showing genome-wide significant GxE effects on the risk of 
abnormal lipid profiles with at least one of the six obesity traits (Supplemental Table 
S4). After LD clumping based on genetic contributions of each variant to the risk of 
dyslipidemia, we detected 20 gene-by-obesity interactions attributable to novel SNPs 
located on SCN1A and SLC12A8 and to lipid-associated SNPs near APOA5, BUD13, 
ZNF259, and HMGCR which were reported in previous GWASs on lipid traits. Table 
2 shows the marginal and gene-by-obesity interactive effects of the newly identified 
loci on the risk of dyslipidemia; we summarized the novel interactions according to 
the discriminators of obesity traits, such as BMI, WC, and WHR. We also estimated 
genomic inflation factors (λ) of each genetic effect, such as marginal, main SNP, and 
interactive effects, in each logistic regression model for testing DG associations and 
GxEs (Supplemental Table S5). Figure 1 (Supplemental Table S6) describes the risk 
of lipid abnormalities for each gene and environmental factor; we estimated the OR 
as the ratio of the probability of dyslipidemia occurring in each exposed group (G≠0 
or E≠0) to the probability in a non-exposed group (G=0 and E=0). 
 
We identified three novel variants interacting with obesity traits to change the risk of 
abnormal elevation of Total-C: rs2878417, rs7702895, and rs7733436. COL4A3BP, 
in particular, exhibited synergistic effects with BMI and WC on the risk of abnormal 
Total-C elevation. For the interaction between HMGCR and WHR, the marginal odds 
ratio (ORD) was 0.81 (95% CI, 0.78-0.84); ORG and ORGxE were 0.72 (95% CI, 0.68-
0.77) and 1.22 (95% CI, 1.13-1.30). As shown in Figure 1.a, the multiplicative effect 
of abdominal obesity was 1.12 (95% CI, 0.96-1.31) for individuals having two wild-
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type alleles at rs7702895 (Supplemental Table S6.a). The effect sizes increased with 
the number of minor alleles: 1.46 (95% CI, 1.28-1.67) for individuals with one minor 
allele and 1.57 (95% CI, 1.26-1.95) for homozygous minor alleles, respectively. 
 
SCN1A marked by rs11890028 was detected as a novel locus interacting with obesity 
to change the risk of abnormal reduction of HDL-C. Although the marginal effect of 
this variant was negligible (P=4.19x10-1), a noticeable GxE effect (P=2.79x10-8) was 
observed in an exhaustive CO analysis. The estimated ORD, ORG, and ORGxE for the 
interaction between SCN1A and BMI were 0.96 (95% CI, 0.91-1.01), 0.92 (95% CI, 
0.87-0.96), and 2.30 (95% CI, 1.98-2.67). As shown in Figure 1.e, the multiplicative 
effect of obesity for common homozygous was 1.42 (95% CI, 1.22-1.65); the effects 
were 1.99 (95% CI, 1.57-2.52) or 6.24 (95% CI, 4.03-9.64) for heterozygous or rare 
homozygous, respectively (Supplemental Table S6.e). 
 
LOC101928271 showed antagonistic effects on the risk of LDL-C abnormalities due 
to BMI. For the identified gene-by-obesity interaction, the estimated ORD, ORG, and 
ORGxE were 0.75 (95% CI, 0.71-0.78), 0.96 (95% CI, 0.88-1.05), and 0.70 (95% CI, 
0.63-0.78), respectively. Figure 1.b (Supplemental Table S6.b), describes the effects 
of overweight class 1; the effect was 1.00 (95% CI, 0.54-1.82) for rare homozygous 
genotypes. For common homozygous or heterozygous genotypes, on the other hand, 
obesity acted as a risk factor for abnormal LDL-C elevation; the multiplicative effect 




We identified six novel SNPs with modifiable effects on the risk of abnormalities in 
TG due to obesity traits: rs1558860, rs180378, rs2075291, rs651821, rs918144, and 
rs77008808. BUD13 and APOA5 have already been reported as lipid-associated loci, 
and the marginal effects of these loci on the risk of abnormal TG elevation were also 
markedly significant in this study. BUD13 marked by rs918144 showed a risky GxE 
effect attributable to WC; ORD, ORG, and ORGxE were 0.71 (95% CI, 0.69-0.73), 0.66 
(95% CI, 0.64-0.70), and 1.17 (95% CI, 1.10-1.24), respectively. As shown in Figure 
1.c (Supplemental Table S6.c), the multiplicative effects of abdominal obesity class 
1 for common homozygous was 1.56 (95% CI, 1.40-1.76); for heterozygous and rare 
homozygous, the estimated effects were 1.68 (95% CI, 1.52-1.86) and 2.12 (95% CI, 
1.76-2.56), respectively. Conversely, APOA5 marked by rs651821 showed protective 
GxE effects due to WHR; ORD, ORG, and ORGxE were estimated to be 1.86 (95% CI, 
1.80-1.93), 2.26 (95% CI, 2.13-2.41), and 0.74 (95% CI, 0.69-0.79). As illustrated in 
Figure 1.f (Supplemental Table S6.f), the multiplicative effects of abdominal obesity 
for each group were as follows: 2.56 (95% CI, 2.20-2.99) for common homozygous, 
1.89 (95% CI, 1.68-2.12) for heterozygous, and 1.39 (95% CI, 1.16-1.66) for people 
with rare homozygous genotypes. 
 
BUD13 and APOA5, besides, were associated with the risk of abnormal Remnant-C 
elevation. BUD13 interacted with WC to modify the risk of dyslipidemia; ORD, ORG, 
and ORGxE were 0.75 (95% CI, 0.73-0.77), 0.73 (95% CI, 0.71-0.75), and 1.16 (95% 
CI, 1.10-1.23), respectively. Figure 1.d (Supplemental Table S6.d) shows the effects 
of abdominal obesity class 2 on the risk of Remnant-C abnormalities: 1.31 (95% CI, 
1.17-1.47) for common homozygous, 1.41 (95% CI, 1.28-1.55) for heterozygous, or 
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1.77 (95% CI, 1.51-2.07) for rare homozygous genotypes. APOA5, on the other hand, 
had an antagonistic effect due to WHR; ORD, ORG, and ORGxE were estimated to be 
1.82 (95% CI, 1.77-1.88), 1.99 (95% CI, 1.89-2.09), and 0.82 (95% CI, 0.78-0.86), 
respectively. Figure 1.g (Supplemental Table S6.g) describes the multiplicative effect 
of abdominal obesity based on WHR; the estimated effects were 2.20 (95% CI, 1.96-
2.46) for people with two wild-type alleles at rs651821. The effects decreased as the 
number of minor alleles increased: 1.85 (95% CI, 1.69-2.03) for heterozygous people 
and 1.48 (95% CI, 1.28-1.71) for people with rare homozygous genotypes. 
 
We ascertained the detected gene-by-obesity interactions from another point; Figure 
2 (Supplemental Table S7) shows the trends of plasma lipid levels due to changes in 
BMI for each subgroup stratified by the number of risk alleles of the identified GxE 
markers. In normal weight (18.5 kg/m2≤BMI<25.0 kg/m2) individuals having no risk 
alleles (low-risk group), HDL-C levels decreased by 0.032 mmol/L (95% CI, 0.030-
0.034 mmol/L) for each unit (1 kg/m2) increase in BMI; the HDL-C decrement level 
was 0.039 mmol/L (95% CI, 0.035-0.043 mmol/L) for people having at least one risk 
allele (high-risk group) and 0.038 mmol/L (95% CI, 0.033-0.043 mmol/L) for upper 
50% of people belong to the high-risk group (higher-risk group). The differences in 
HDL-C decrement levels for each genetic group were more apparent in obese people. 
For individuals with BMI over 25 kg/m2, the decrements in HDL-C for the low-risk, 
high-risk, and higher-risk group were 0.004 mmol/L (95% CI, 0.002-0.006 mmol/L), 
0.014 mmol/L (95% CI, 0.010-0.018 mmol/L), and 0.017 mmol/L (95% CI, 0.012-
0.022 mmol/L). Similarly, we ascertained that TG increments were different for each 
genetic group; the increment trends were also more apparent in obese individuals. 
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2.3. Genetic Contribution of Gene-by-Obesity Interactions 
Table 3 presents the genetic contributions due to marginal associations and gene-by-
obesity interactions to abnormal lipid profiles. We suggested a proportion of the total 
heritability for each lipid explained by 1) GWAS-identified SNPs, 2) novel GxE loci, 
and 3) the combined set of lipid-associated and gene-by-obesity interactive variants, 
so-called the total genetic impact. The total and SNP-based heritability of the risk of 
abnormal Total-C elevation was approximately 35.5% and 17.7-24.9%, respectively, 
after adjusting the risk for age, age2, and sex. The genetic contributions increased if 
we considered both marginal genetic associations and gene-by-obesity interactions, 
with differences between the GWAS-identified and total genetic impact of 1.1-1.9%. 
The total and SNP-based heritability of the risk of LDL-C abnormalities, on the other 
hand, was approximately 31.7% and 17.2-25.6%, respectively. For each obesity trait, 
the total genetic contributions, including interactions, were 0.9-2.4% higher than the 
marginal genetic impacts due to direct associations only. 
 
The contributions of the combined set of both GWAS-identified and GxE SNPs were 
markedly higher when several independent gene-by-obesity interactions present for 
each pair of lipids and environmental factors. Genetic contributions to the risk of TG 
abnormalities are described in Figure 3.a, 3.b, and 3.c (Table 3). The detected genetic 
factors accounted for approximately 38.3% of the total variance of abnormal TG risk 
after adjusting for age, age2, and sex. Genetic markers located on genome-wide dense 
SNP microarrays accounted for 18.4-26.4% of the overall variance of the risk of TG 
abnormalities. About 36.6% of the total heritability was due to 40 independent SNPs 
identified by GWASs; genetic contributions increased to 47.1% when we considered 
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the interactions of APOA5 or BUD13 with WC. The total genetic impacts, in similar, 
increased from 39.3% to 58.0% when we considered both marginal associations and 
newly found genetic interactions attributable to WHR. For Caucasians, the additional 
heritability of TG due to the interactions of GxE variants with WC or WHR was 5.8% 
and 9.1%; the gain was 10.6% and 18.7% for Koreans, respectively. 
 
Genetic contributions to the risk of abnormal elevation of Remnant-C are described 
in Figure 3.d (Table 3). The detected genetic factors explained approximately 48.6% 
of the total variance after adjusting for age, age2, and sex. Genetic markers genotyped 
on SNP microarrays accounted for 11.3-14.2% of the overall variance for Remnant-
C. About 38.5% of the total heritability was explained by 59 GWAS-identified SNPs 
only. When marginal associations and interactions of APOA5 or BUD13 with WHR, 
which change abnormal Remnant-C risk were considered, the genetic contributions 
increased to 47.8%; there were 9.3% differences between marginal and total genetic 




One of the main purposes of human genome studies is to personalize treatments and 
health guidelines due to one’s genetic constitution. GWISs are approaches intended 
for achieving this end, particularly when genetic loci interacting with modifiable risk 
factors are investigated at genome-wide levels. Such studies permit the identification 
of higher-risk or lower-risk individuals depending on changes in known risk factors. 
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In this study, we identified novel and known genes interacting with obesity traits for 
changing the risk of dyslipidemia. We also replicated our findings using independent 
Korean genome cohorts and assessed how much phenotypic variance or heritability 
was additionally explained by considering the gene-by-obesity interactions. 
 
Our study has focused on increasing power to detect gene-by-obesity interactions by 
applying a variety of strategies for testing GxEs. We carried out emerging exhaustive 
scans and two-step methods in parallel because each analytical GxE model provided 
differential power to find interactions, mainly according to marginal genetic and GxE 
effects. We tested interactions of SNPs at a genome-wide scale with various obesity 
traits, including Korean-specific parameters defined by additional ranges of BMI and 
WC. Furthermore, we adopted liberal cut-offs and stepwise penalties due to marginal 
genetic p-values as well as the standard genome-wide significance level to find gene-
by-obesity interactive loci influencing the risk of dyslipidemia. For GxE studies, type 
1 errors are generally considered to be less problematic than possible underpowered 
findings (105); applying multiple analytical models is advantageous to identify GxEs 
at a genome-wide level. By replication and stratified analyses for a candidate region 
localized by previous studies, we can further verify the identified interactions. 
 
Our findings reveal a genome-wide set of SNPs with a wide range of marginal effects 
on the risk of dyslipidemia. We identified novel GxE variants located on SCN1A and 
SLC12A8 with few or no direct association with lipid parameters as well as gene-by-
obesity interactions related to lipid-associated genes reported in previous GWASs on 
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lipids: APOA5, BUD13, ZNF259, and HMGCR. We identified SCN1A and SLC12A8 
through exhaustive CO analyses, while all other GxEs attributable to lipid-associated 
loci were detected by using two-step methods, such as CT1, CT2, and EDGxE. These 
trends are consistent with the results of earlier simulation studies on statistical power 
for GxE detection, which showed that exhaustive CO analysis is more powerful than 
other two-step methods when the marginal effects of genetic variants are small (30). 
To our knowledge, SCN1A and SLC12A8 have not been reported in previous studies 
to be associated with any lipid parameters. 
 
We replicated our findings in four independent Korean genome cohorts; one strength 
of using cohorts formulated on identical protocols is the ability to examine gene-by-
obesity interactions with high-quality health-related outcome variables, genetic and 
environmental factors. In addition, conducting a meta-analysis with the independent 
Korean cohorts permitted the estimation of more precise effects of susceptibility loci 
interacting with obesity traits. We also classified study populations into three groups 
according to the number of risk alleles at GxE loci and compared the changes in lipid 
levels when BMI, WC, and WHR increased by one unit among the three groups. The 
identified gene-by-obesity interactions were ascertained from another point of view 
by this comparison; the increment of the number of risk alleles worsened the changes 
in lipids due to the elevation of obesity indices. 
 
Although generating interesting findings, our approaches for testing gene-by-obesity 
interactive effects on lipid profiles have some limitations. Our study did not include 
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GxEs due to low-frequency and rare variants (MAF<0.01); we also did not use other 
essential obesity indices, such as body fat percentage and visceral fat level. We only 
focused on GxE effects due to a set of common variants since our study populations 
did not include enough information for low-frequency and rare variants. In addition, 
current analytical methods do not offer adequate power to detect GxE effects of rare 
variants. The latest approaches using gene-set analyses and the sum of powered score 
tests are also limited to test GxEs at a variant-by-variant level (134, 135). Some rare 
variants in NPC1L1, however, are known to be related to cholesterol absorption and 
LDL-C levels (136), and the interplay between rare variants and obesity traits might 
play a role in regulating lipid levels. 
 
Besides, our new findings primarily concern GxEs based on indirect obesity indices; 
BMI, WC, and WHR are surrogate measurements of overall and abdominal adiposity 
(137). Other vital measures of adipose tissue distribution, including visceral fat level 
and body fat percentage, have been reported to be related to higher risks of CVD and 
metabolic syndrome in large-scale epidemiological studies (138-140); these indices, 
however, were not addressed in this study. Even though we used commonly accepted 
guidelines of the NIH and KSSO (121, 122), the cut-offs to define obesity traits were 
somewhat arbitrary. Considering the evidence that a cardio-metabolic abnormality is 
more closely linked with body shape or body fat distribution than with conventional 
obesity indices (141, 142), interactions of genetic susceptibility loci of dyslipidemia 




Our ability to extend the novel GxE findings from Korean populations to other ethnic 
groups is limited by the differences in MAFs of each variant, distributions of obesity 
traits, and prevalence of dyslipidemia. Our findings were estimated and reconfirmed 
in four independent cohorts sharing protocols to measure phenotypes and genotypes. 
The detected gene-by-obesity interactions on dyslipidemia might not be supported if 
racial differences in lipids and distributions of genetic and environmental factors are 
considered. ZNF259 marked by rs2075291, for example, could be a useful target for 
managing TG in Korean population; the ZNF259-by-WHR interactive impact on the 
risk of TG abnormalities was 3.4%. This locus, however, is not a suitable therapeutic 
target for the other ethnic groups; the minor allele is infrequent for South Asians and 
too rare for Europeans, Americans, and Africans (Table 3). Conversely, some minor 
findings in this study could be useful in other ethnic groups. 
 
Many human traits or complex diseases are considered consequences of both genetic 
and environmental factors. Thus, GxE analyses may hold the key to further insights 
on disease biology and the development of better prediction models. Our exploration 
of GxEs at a genome-wide level in Koreans revealed novel genetic susceptibility loci 
of dyslipidemia interacting with modifiable obesity traits. Our results were replicated 
in independent genome cohorts and confirmed by comparing changes in lipid levels 
attributable to an increment of obesity for each genetic subgroup. Compared to lipid-
associated loci having only marginal genetic effects, the inclusion of gene-by-obesity 
interactive loci explained more of the total and genetic variances of each lipid. Based 
on the different MAFs between Caucasians and Asians, besides, Asians have a higher 
risk of dyslipidemia, particularly for TG, even with a small increase in obesity traits. 
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These newly identified genetic interactions with obesity traits can be used to classify 
individuals into higher-risk or lower-risk groups and to personalize health guidelines 




















A Genome-Wide Search for 
Gene-by-Lifestyle Interaction Loci of Hypertension 
 
1. Materials and Methods 
 
1.1. Participants 
A total of 18,025 individuals of Korean descent from four independent cohort studies 
with a genome-wide set of variants were included in this gene-by-lifestyle interaction 
study on HBP: 4,637 individuals from the Ansan cohort, 4,205 individuals from the 
Ansung cohort, 3,700 individuals from the urban cohort, and 5,483 individuals from 
the rural cohort. Participants who have suffered cancer or diabetes or any CVDs were 
excluded from this study; people taking any antihypertensive drugs were considered 
as patients with hypertension (Supplemental Figure S9). The baseline characteristics 
of each cohort study are described in Table 4; a total of 15,954 people were included 
in this study on hypertension. 
 
Participants in the Ansan and Ansung cohort, the reference set, were aged about 40-
69 years and recruited from industrialized suburban and rural regions of the Republic 
of Korea. Participants in the urban and rural cohorts, the replication set, on the other 
hand, were aged over 40 years; they were recruited from medical institutions located 
in urban and rural areas of Korea. These four Korean genome cohort studies are part 
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of the KoGES, an ongoing population-based cohort study initiated in 2001 to provide 
evidence of chronic diseases among Koreans. The research protocols and data in this 
study have followed the Declaration of Helsinki principles; this study was approved 
by the IRB of Seoul National University (IRB number: E1805-003-001). 
 
1.2. Measurements 
Data about health status, health-related behaviors, medical histories, and medications 
were collected through standardized questionnaires. Trained experts at each medical 
center conducted anthropometric measurements, specimen collection, and laboratory 
tests. All participants provided informed consent for the baseline data and specimens; 
more detailed protocols were presented in previous reports (118, 119). SBP and DBP 
were assessed three times on both arms to make the valid measures; the higher value 
was confirmed as an individual’s BP level. Detailed protocols for measuring BP have 
followed the AHA guidelines for managing HBP (78). We determined mean arterial 
pressure (MAP) as the sum of DBP and PP divided by three; Mid-BP was the average 
of SBP and DBP. We decided an individual’s habits of cigarette smoking and alcohol 
consumption through standardized questionnaires. BMI or WHR, on the other hand, 
were calculated using directly measured height, weight, WC, and HC. 
 
1.3. Phenotypes 
We defined hypertension based on clinical cut-offs of high-risk CVD groups reported 
in the AHA guidelines (78): HBP-S1 (130≤SBP<140 mmHg or 80≤DBP<90 mmHg) 
and HBP-S2 (SBP≥140 mmHg or DBP≥90 mmHg). Individuals who have taken any 
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antihypertensive drugs were considered as patients with HBP in statistical analyses. 
We decided behavioral traits of smoking using self-report of cigarette smoking: ever 
and current smoking. We also decided behavioral traits of drinking using self-report 
of alcohol consumption: ever drinking, current drinking, moderate drinking, low-risk 
drinking, heavy drinking, and binge drinking (Supplemental Table S1). We followed 
clinical guides of the National Institute on Alcohol Abuse and Alcoholism (NIAAA) 
to decide cut-off points for alcohol consumption. We defined obesity traits based on 
clinical guidelines of the NIH and KSSO (121, 122): underweight, overweight class 
1, overweight class 2, obesity, abdominal obesity class 1, abdominal obesity class 2, 
and abdominal obesity based on WHR (Supplemental Table S1). 
 
1.4. Genotype Information 
We used the following genome-wide dense SNP microarrays for generating genotype 
data: the Affymetrix Genome-Wide Human SNP Array 5.0 for the Ansan and Ansung 
cohorts, version 6.0 for the urban cohort and a part of the rural cohort (n=1,816), and 
the Illumina HumanOmni1-Quad BeadChip for the rest of the rural cohort (n=3,667). 
Any marker violating Hardy-Weinberg equilibrium (p-value<1x10-6), with genotype 
call rates below 95%, or with MAFs below 0.01 were excluded. After quality control, 
the remaining SNPs were imputed by using the haplotypes phase I in NCBI build 37 
(GRCh37/hg19) of the Asian references from the 1000 Genomes Project. SHAPEIT2 
and IMPUTE2 were used for the haplotype phasing and imputation (123, 124). SNPs 
with quality scores higher than 0.6 were retained, yielding 4,780,608 variants for the 
reference set and 5,729,661 variants for the replication set. A total of 3,914,038 SNPs 
were selected as the final genetic markers after comparing each cohort. 
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1.5. Statistical Analyses 
The risk of hypertension was adjusted for age, age2, sex, and BMI to test interactions 
of GxE SNPs with traits of smoking or drinking; the logarithm of OR was corrected 
by using a logit model. For gene-by-obesity interactions, on the other hand, HBP risk 
was adjusted for age, age2, and sex; the logarithm of OR was also corrected by using 
a logit model. We conducted marginal DG and EG analyses for the 3.9 million SNPs 
before GWISs. Genetic markers associated with both BP and environmental factors 
(p-value<1x10-3) were excluded to reduce potential pleiotropy. 
 
We conducted exhaustive scans, such as CC, CO (106), and EB tests (107), and two-
step methods (DG1, DG2 (110), EG2 (111), H2 (105), CT1, CT2 (112), and EDGxE 
(30)) in parallel. After finding novel GxE variants, we applied the standard genome-
wide significance level (p-value<5x10-8) for exhaustive scans. For step-1 of the DG1, 
DG2, EG2, and H2, we assumed a screening cut-off of 1x10-4; the subset of screened 
SNPs was examined for step-2 at a more liberal cut-off (0.05 divided by the number 
of screened SNPs) (105). We applied weighted hypothesis testing methods in step-2 
of CT1, CT2, and EDGxE rather than testing only variants passing a screening step; 
stepwise penalties according to the marginal p-value were applied for SNPs in step-
2 (125). One of a pair of the identified SNPs was removed if the LD was greater than 
0.5, which means a VIF was greater than 2, for LD clumping. We found novel GxEs 
by using the reference set; all detected GxEs were confirmed by using the replication 




1.6. Methods of Evaluating Impacts 
We used the simplified equation 2p(1-p)[log(OR)]2 to estimate the genetic variances 
due to genetic susceptibility SNPs; p is the MAF of a variant and OR is the estimated 
marginal effect (128). The contribution of GxE loci, on the other hand, was estimated 
using the equation 2p(1-p)[log(ORG)]2/VP+2ep[(1-p)+2p(e-1)2][log(ORGxE)]2/VP; in 
this equation, VP is the phenotypic variance, e is the prevalence of an environmental 
factor, ORG and ORGxE are estimated genetic and GxE effects. We estimated the total 
HBP heritability from the Healthy Twin Study (130, 131) by using GenABEL (129). 
We also used GCTA (132) to estimate the SNP-based heritability due to the GWAS-
variants on SNP microarrays. We cited the prevalence of HBP-S1 and HBP-S2 using 
information from the KNHANES to transform the estimate of variance explained on 
the observed scale to that on the underlying scale (143). According to the KNHANES 




2.1. Characteristics of the Study Populations 
Table 4 describes the baseline characteristics of the participants in four independent 
Korean genome cohorts. We presented age, sex, obesity-related traits, and BP-related 
traits adjusted for age, age2, sex, and BMI. As mentioned above, SBP and DBP have 
been directly measured three times from each participant; the highest BP level of the 
three measures was confirmed as the valid level for each SBP or DBP. MAP, PP, and 
Mid-BP, on the other hand, have been indirectly assessed: 1) MAP is the sum of DBP 
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and PP divided by three, 2) PP is the value of SBP minus DBP, and 3) Mid-BP is the 
average of SBP and DBP. 
 
2.2. Identification of Gene-by-Lifestyle Interactive Loci 
We identified 62 SNPs showing genome-wide significant GxE effects on the risk of 
hypertension with at least one of the lifestyle factors, including two traits of cigarette 
smoking, six traits of alcohol consumption, and seven traits of obesity (Supplemental 
Table S8). After LD clumping due to genetic contributions of each SNP to HBP risk, 
we detected 24 gene-by-lifestyle interactions of novel variants (BRAP, SH2B3), BP-
associated SNPs (ATP2B1), alcohol-associated variants (ALDH2, CUX2, HECTD4 
(C12orf51), MYL2, OAS3), and SNPs related to obesity (ST5). Table 5 describes the 
marginal and gene-by-lifestyle interactive effects of the newly identified variants on 
the risk of hypertension; detailed results are presented in Supplemental Table S8. As 
shown in Supplemental Table S9, we estimated genomic inflation factors (λ) of each 
genetic effect, such as marginal, main SNP, and gene-by-lifestyle interactive effects, 
in each logistic regression model for testing DG associations and GxEs. 
 
Figure 4 (Supplemental Table S10) describes the risk of HBP-S1 or HBP-S2 for each 
genetic and environmental factor; we estimated ORs as the ratio of HBP probability 
occurring in exposed groups (G≠0 or E≠0) to the probability for non-exposed groups 
(G=0 and E=0). DCC marked by rs9950661 interacted with ever smoking to change 
the risk of HBP-S1; CT1 and CT2 methods observed the variant. The ORD, ORG, and 
ORGxE for the interaction between DCC and ever smoking were 0.87 (95% CI, 0.85-
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0.90), 0.89 (95% CI, 0.86-0.92), and 0.90 (95% CI, 0.86-0.95). Multiplicative effects 
were described in Figure 4.a (Supplemental Table S10.a). For common homozygous, 
the effect was 1.22 (95% CI, 1.17-1.27); the effect was 1.16 (95% CI, 1.11-1.21) and 
1.23 (95% CI, 1.12-1.35) for heterozygous and rare homozygous genotypes. 
 
RPH3A marked by rs886476 showed antagonistic effects on the risk of HBP-S1 due 
to low-risk drinking. For this interaction, the ORD, ORG, and ORGxE were 0.91 (95% 
CI, 0.89-0.94), 0.93 (95% CI, 0.91-0.96), and 0.64 (95% CI, 0.60-0.68), respectively. 
As shown in Figure 4.b (Supplemental Table S10.b), the multiplicative effect of low-
risk drinking was 1.27 (95% CI, 1.19-1.34), 1.13 (95% CI, 1.05-1.22), and 1.11 (95% 
CI, 0.94-1.30) for common homozygous, heterozygous, and rare homozygous. 
 
MYL2 marked by rs4766517, on the other hand, had synergistic effects on the risk of 
HBP with heavy drinking. The locus already had been reported to be associated with 
alcohol consumption in previous GWASs (144). For the GxE, the estimated ORD was 
1.00 (95% CI, 0.97-1.02); ORG and ORGxE were estimated to be 0.97 (95% CI, 0.94-
1.00) and 1.38 (95% CI, 1.31-1.45). As described in Figure 4.c (Supplemental Table 
S10.c), the multiplicative effect of heavy drinking was 1.14 (95% CI, 1.05-1.24) for 
individuals with two wild-type alleles at rs4766517. The effects, however, increased 
with the number of minor alleles; the effects were 1.21 (95% CI, 1.14-1.27) and 1.33 
(95% CI, 1.24-1.42) for heterozygous and homozygous minor alleles. 
 
Antagonistic effects were induced by the interaction between rs79977578 located on 
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KLF4 and moderate drinking for the risk of hypertension. The estimated ORD, ORG, 
and ORGxE were 0.97 (95% CI, 0.93-1.01), 1.19 (95% CI, 1.13-1.26), and 0.60 (95% 
CI, 0.55-0.66) for the interplay, respectively. As shown in Figure 4.d (Supplemental 
Table S10.d), the multiplicative effect on HBP-S1 was 1.06 (95% CI, 1.02-1.09) for 
individuals having two wild-type alleles, 0.81 (95% CI, 0.74-0.87) for heterozygous, 
and 0.95 (95% CI, 0.70-1.30) for rare homozygous genotypes. 
 
For HBP-S2 risk, we detected four novel gene-by-obesity interactions; we could not 
find any loci interacting with cigarette smoking or alcohol consumption. ST5 marked 
by rs140343181 has synergistic effects with obesity on the risk of HBP-S2; the ORD, 
ORG, and ORGxE were 0.90 (95% CI, 0.79-1.02), 0.79 (95% CI, 0.69-0.91), and 4.23 
(95% CI, 3.25-5.50), respectively. RP11-981P6.1 marked by rs1689040 had a risky 
GxE effect due to obesity; the ORD, ORG, and ORGxE were 0.86 (95% CI, 0.83-0.88), 
0.85 (95% CI, 0.82-0.87), and 1.34 (95% CI, 1.18-1.53). Multiplicative GxE effects 
of obesity for common homozygous, heterozygous, and rare homozygous were 1.69 
(95% CI, 1.44-1.99), 2.18 (95% CI, 1.90-2.51), and 2.37 (95% CI, 1.87-3.00); more 
detailed features were described in Figure 4.e (Supplemental Table S10.e). 
 
ATP2B1, a locus known to be associated with BP (90, 145), gave a synergistic effect 
with abdominal obesity on the risk of HBP-S2. For the interaction between ATP2B1 
and abdominal obesity, the ORD was 0.85 (95% CI, 0.83-0.88); ORG and ORGxE were 
estimated to be 0.82 (95% CI, 0.79-0.86) and 1.13 (95% CI, 1.07-1.20). As described 
in Figure 4.f (Supplemental Table S10.f), the multiplicative GxE effect of abdominal 
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obesity was 1.47 (95% CI, 1.35-1.61) for people having two wild-types at rs2681472. 
The effect sizes of abdominal obesity increased with the number of risky alleles; the 
effects were 1.63 (95% CI, 1.50-1.78) and 1.73 (95% CI, 1.47-2.03) for heterozygous 
and homozygous risky alleles. 
 
MYL2 also showed synergistic effects on HBP-S2 risk with abdominal obesity based 
on WHR. For the interaction, the ORD was 0.89 (95% CI, 0.86-0.93); ORG and ORGxE 
were 0.80 (95% CI, 0.74-0.86) and 1.20 (95% CI, 1.10-1.32), respectively. As shown 
in Figure 4.g (Supplemental Table S10.g), the multiplicative effect due to abdominal 
obesity was 1.78 (95% CI, 1.66-1.91) for people with two wild-types at rs12229654. 
The effect sizes due to abdominal obesity increased with the number of minor alleles; 
the effect was estimated to be 1.95 (95% CI, 1.72-2.21) and 2.68 (95% CI, 1.65-4.35) 
for heterozygous and homozygous minor alleles. 
 
2.3. Genetic Contribution of Gene-by-Lifestyle Interactions 
Table 6 presents the contributions due to marginal associations and gene-by-lifestyle 
interactions to the risk of hypertension. We suggest the proportion of total heritability 
for each stage of hypertension by 1) GWAS-identified SNPs, 2) novel GxE loci, and 
3) the combined set of both BP-associated and gene-by-lifestyle interactive variants, 
so-called the total genetic impact. The total and SNP-based HBP-S1 heritability was 
approximately 39.3% and 14.6-26.7%, after adjusting HBP-S1 risk by age, age2, and 
sex. The genetic contribution increased with a difference between GWAS-identified 
and total genetic impact of 0.3-2.1% if we considered both marginal associations and 
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interactions of GxE variants with cigarette smoking or alcohol consumption. We also 
described the genetic contribution attributable to marginal associations and gene-by-
lifestyle interactions in Figure 5. 
 
For HBP-S2 risk, there were four novel gene-by-obesity interactions of variants with 
GxE impacts of 0.2-1.2%. The total and SNP-based heritability of HBP-S2 was about 
29.0% and 16.7-25.9% after adjusting the risk of hypertension by age, age2, and sex 
(Table 6). As shown in Figure 5, the genetic contribution increased if we considered 
both marginal genetic and gene-by-obesity interactive loci, with differences between 
the impact due to the GWAS-identified variants and total genetic impact of 1.1-1.2%. 
Unfortunately, we could not detect any genetic variants for HBP-S2 interacting with 
cigarette smoking or alcohol consumption. 
 
Some variants show racial differences in MAFs and GxE impacts on the risk of HBP: 
rs10849933 (CUX2), rs79977578 (KLF4), and rs12229654 (MYL2). CUX2, marked 
by rs10849933, for example, shows a small impact for Koreans compared with other 
ethnic groups, such as Europeans or Americans. The minor allele is rare for Koreans; 
the frequency is 0.32 for Koreans, 0.83 for Europeans, and 0.83 for Americans. MAF 
of rs79977578 near KLF4, conversely, is extremely low for Americans or Europeans 
or Africans; the frequency is 0.03 for Americans and approaching 0.00 for Europeans 
and Africans. Thus, KLF4 shows the more significant GxE impacts for Koreans, East 
Asians, and South Asians. For gene-by-obesity interactions on HBP-S2, on the other 
hand, MYL2 has the more significant impact for Koreans and East Asians compared 
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with other ethnic groups; for South Asians, Europeans, Americans, and Africans, the 




We identified novel and known genes modifying the risk of hypertension for Koreans 
by interacting with lifestyle factors, such as cigarette smoking, alcohol consumption, 
and obesity. Our findings were replicated in four independent Korean cohort studies 
with a genome-wide set of variants. We also assessed how much phenotypic variance 
or heritability of HBP was additionally explained by considering the identified gene-
by-lifestyle interactions. About 0.3-2.1% of the heritability, besides, was additionally 
explained by considering both marginal genetic associations and genetic interactions 
with cigarette smoking or alcohol consumption or obesity. 
 
In this study, we have identified several GxE variants with a wide range of marginal 
genetic effects on the risk of hypertension; our findings have covered a genome-wide 
set of SNPs. There were novel GxE markers located on BRAP and SH2B3 with little 
or no direct genetic associations with BP parameters as well as genetic loci associated 
with BP (ATP2B1), alcohol consumption (ALDH2, CUX2, HECTD4, MYL2, OAS3), 
and obesity (ST5); these variants have already been reported in previous GWASs (90, 
144, 145). We have detected most GxE variants through exhaustive CO tests; in other 
word, the identified SNPs had a weak marginal effect on HBP and had a rare chance 
to be detected through standard CC tests. In general, CO analyses give much greater 
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power of testing interactions than the other exhaustive scans (30). To our knowledge, 
BRAP and SH2B3 have not been previously reported in GWASs on any BP traits. 
 
In this GWIS, we have focused on increasing the power to test interactions between 
genes and lifestyle factors by applying various analytical GxE models. We conducted 
several exhaustive scans and two-step approaches as possible; each statistical model 
provided differential power to detect GxEs across a range of magnitudes for marginal 
genetic and interactive effects of genetic susceptibility loci. We explored interactions 
of a genome-wide set of variants with several behavioral traits of cigarette smoking, 
alcohol consumption, and obesity, including Korean-specific indices determined by 
additional ranges of BMI and WC. As well as the standard genome-wide significance 
level (p-value<5x10-8), we also adopted liberal thresholds and stepwise penalties due 
to marginal p-values for the detection of gene-by-lifestyle interactive loci modifying 
the risk of hypertension for Koreans. 
 
Although the replication of novel findings has not been widely required for reporting 
GxEs, we replicated our findings in four independent Korean genome cohort studies. 
We believe replications in GxE studies are as important as in GWASs, especially for 
GWISs; the possible type 1 errors or false-positive findings induced by using various 
analytical GxE models need to be verified by replications and stratified analyses for 
candidate regions localized by previous researches. The four Korean cohorts, on the 
other hand, have shared the research protocols, phenotypic data, and genotypes; one 
strength of using cohorts sharing identical protocols is the ability to test interactions 
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with high-quality health outcomes, genetic and environmental factors. Moreover, we 
conducted meta-analyses with the Korean cohort studies; these approaches permitted 
the more precise effect estimates of BP-loci interacting with lifestyle factors. 
 
There are some limitations in this study; first of all, we only focused on the gene-by-
lifestyle interactions due to a set of common variants since our study populations did 
not include enough information for rare variants (MAF<0.01). Unfortunately, current 
statistical methods do not provide adequate power to detect GxEs attributable to low-
frequency or rare variants; the latest methods based on gene-set analyses and the sum 
of powered score tests are also limited for testing GxEs, variant by variant (134, 135). 
There is the possibility that rare genetic markers modifying HBP risk due to lifestyle 
may exist; most of the identified GxE loci in this study had a weak marginal genetic 
effect on the risk of HBP-S1 or HBP-S2. 
 
Furthermore, our findings primarily concern interactions based on indirect measures 
of cigarette smoking, alcohol consumption, and obesity. We decided behavioral traits 
of cigarette smoking or alcohol consumption by using self-reports only; daily intakes 
of alcohol, the main index for determining behavioral traits of alcohol consumption, 
were also calculated by using a self-reported alcohol intake. For obesity, on the other 
hand, we considered surrogate measures of overall and abdominal adiposity, such as 
BMI, WC, and WHR (137). We did not consider other vital indices, such as body fat 
percentage and visceral fat level; these parameters had been reported to be related to 
higher CVD risk and metabolic syndrome (138-140). Even though we have followed 
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commonly accepted guides of the NIAAA, NIH, and KSSO to define environmental 
factors (121, 122), the thresholds were somewhat arbitrary. If we had any indicators 
which directly reflect lifestyle factors, such as chemicals in tobacco, body or visceral 
fat level, we could determine the more precise indices of each environmental factor; 
it may provide the higher power to detect GxEs. 
 
Our novel findings were estimated and reconfirmed in four Korean genome cohorts 
formulated on identical protocols. The identified gene-by-lifestyle interactions were 
limited to be applied to other ethnic groups having differences in MAFs of each GxE 
variant, distributions of lifestyle factors, and prevalence of HBP. ALDH2 marked by 
rs112605264, for example, could be the more useful therapeutic target for managing 
HBP for Europeans than for Koreans; the variant is most common for individuals of 
European descent (MAF=1.00). For gene-by-obesity interactions, on the other hand, 
rs12229654 located on MYL2 shows the greater impact for Koreans and East Asians 
compared with other ethnic groups; the minor allele is extremely rare for Europeans, 
Americans, Africans, and South Asians (MAF=0.00). It may be useful in the Korean 
and East Asian populations but not for the other ethnic group. 
 
Human complex diseases are known to be related to both genetic and environmental 
factors; we may have further insights on disease biology and develop more accurate 
prediction models by exploring GxEs. GWISs are approaches particularly designed 
for the main purposes of human genome studies: to personalize treatment and health 
guidelines according to an individual's genetic constitution. Such studies permit the 
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identification of higher-risk or lower-risk groups depending on a known modifiable 
risk factor. Our study on gene-by-lifestyle interactions has revealed variants of HBP 
interacting with behavioral factors, such as cigarette smoking, alcohol consumption, 
and obesity. Compared to genetic loci having marginal effects only, the inclusion of 
GxE variants clearly explained more of the total and genetic variances of HBP. These 
newly identified gene-by-lifestyle interactions could be used to classify individuals 
into different risk groups and to give personalized guidelines for managing HBP and 

















A Genome-Wide Interaction Scan for 
Lipids and Blood Pressure Levels 
 
1. Materials and Methods 
 
1.1. Participants 
A total of 18,025 individuals from four independent Korean genome cohorts, as same 
as the population of our previous GWISs, were included in this study on quantitative 
lipids and BP levels: individuals from the Ansan cohort (n=4,637), the Ansung cohort 
(n=4,205), the urban cohort (n=3,700), and the rural cohort (n=5,483). For the study 
on lipid levels, individuals who have suffered cancer or diabetes were excluded; we 
also excluded people taking any lipid-lowering drugs (Supplemental Figure S12). In 
the study on BP levels, individuals who have experienced cancer or diabetes or CVD 
were excluded. For people taking any kind of antihypertensive medication, we added 
10 mmHg and 5 mmHg to observed SBP and DBP levels, respectively (90, 146, 147) 
(Supplemental Figure S13). Table 7 shows the baseline characteristics of the Korean 
genome cohorts for each quantitative GWIS. A total of 15,754 people were included 
in the GWIS for lipids; a total of 15,954 individuals, on the other hand, were included 
in the GxE study on quantitative BP levels. 
 
People, aged 40-69 years, were included in the Ansan and Ansung cohorts; they were 
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recruited from industrialized suburban and rural areas of the Republic of Korea. For 
the urban and rural cohorts, on the other hand, individuals, aged over 40 years, were 
recruited from medical centers located in urban and rural regions of Korea. The four 
Korean cohorts are part of the large-scale population-based cohort study, the KoGES. 
The research protocols and data in these studies followed the Declaration of Helsinki 




The overall protocols for this study were also described in our previous studies; more 
detailed protocols to collect an individual’s data on health status, behaviors, medical, 
and medication histories are described in previous reports (118, 119). Total-C, HDL-
C, and TG levels were measured by using traditional enzymatic methods in the blood 
samples drawn after an 8-hour fast. We calculated LDL-C levels by the Friedewald’s 
formula (120); Remnant-C levels were determined as a quantitative level of Total-C 
minus HDL-C minus LDL-C (42, 44). SBP and DBP levels, on the other hand, were 
measured as instructed in the AHA guides (78). Behavioral factors, such as cigarette 
smoking and alcohol consumption, were assessed by the standardized questionnaire. 
We calculated obesity indicators, such as BMI and WHR, by using directly measured 
height, weight, WC, and HC. 
 
1.3. Phenotypes 
We used the following quantitative lipids for testing gene-by-obesity interactions at 
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a genome-wide scale: Total-C, HDL-C, LDL-C, TG, and Remnant-C (mmol/L). For 
this study, we excluded individuals who have suffered cancer or diabetes; individuals 
taking any lipid-lowering medications were also excluded. For the gene-by-lifestyle 
interaction study on BP levels, we used SBP and DBP (mmHg) as outcome variables. 
We also excluded individuals who have experienced cancer or diabetes or any CVDs. 
For people taking any antihypertensive drugs, we added 10 mmHg to observed SBP 
and 5 mmHg to observed DBP (90, 146, 147). The same behavioral factors with our 
previous GWISs were used in this GWIS: cigarette smoking (ever, current smoking), 
alcohol consumption (ever, current, moderate, low-risk, heavy, binge drinking), and 
obesity (underweight, overweight class 1, 2, obesity, abdominal obesity class 1, 2, or 
abdominal obesity based on WHR). The detailed cut-off points for behavioral factors 
are described in Supplemental Table 1. 
 
1.4. Genotype Information 
Genome-wide dense SNP microarrays were used to create genotype information. We 
have already introduced the SNP microarrays in our previous GWISs: the Affymetrix 
Genome-Wide Human SNP Array version 5.0, 6.0, and the Illumina HumanOmni1-
Quad BeadChip. We excluded any variant violating Hardy-Weinberg equilibrium (p-
value<1x10-6) or with genotype call rates below 95% or with MAF below 0.01. The 
remaining SNPs were imputed by the 1000 Genomes Project’s haplotypes phase I in 
NCBI build 37 (GRCh37/hg19) of the Asian references. SHAPEIT2 and IMPUTE2 
were used for phasing and imputation (123, 124). Only genetic variants with quality 
scores higher than 0.6 were retained, yielding 4,780,608 and 5,729,661 SNPs for the 
reference and replication set. A total of 3,914,038 variants having imputation quality 
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higher than 0.6 were selected as the final genetic variants after comparing each set. 
 
1.5. Statistical Analyses 
We carried out two independent GWISs in this study: GWISs for 1) gene-by-obesity 
interactions on quantitative TG and 2) gene-by-lifestyle interactions on quantitative 
BP levels. Compared with our previous GxE findings, we tested whether the different 
scales of outcome variables (continuous vs. dichotomous) had affected the results of 
GWISs. In the GWIS for TG, we transformed continuous TG, a non-normalized trait, 
into a logarithmic scale and adjusted the transformed TG for age, age2, sex, and each 
obesity trait, one by one. In the GWIS for BP, on the other hand, SBP and DBP were 
adjusted for age, age2, sex, and BMI; we adjusted each BP for age, age2, and sex for 
testing gene-by-obesity interactions. We also carried out DG and EG tests for the 3.9 
million SNPs before quantitative GWISs. Genetic markers associated with both one 
of the outcomes and environmental factors (p-value<1x10-3) were excluded to reduce 
the potential pleiotropy. 
 
We conducted CC, DG2 (110), EG2 (111), H2 (105), and EDGxE (30) methods, the 
analytical approaches that could be extended to GWISs for quantitative phenotypes, 
in parallel. After detecting novel GxE variants, we applied the standard genome-wide 
significance level (p-value<5x10-8) for a CC analysis. For the screening step of DG2, 
EG2, and H2 analyses, we assumed a screening cut-off of 1x10-4; the subset of SNPs 
passing step-1 was tested for step-2 at the more liberal threshold (0.05 divided by the 
number of screened SNPs) (105). We applied weighted hypothesis testing in step-2 
58 
 
of EDGxE rather than testing only variants passing step-1; stepwise penalties due to 
the marginal p-value were applied for each variant in step-2 (125). One of the pair 
of identified SNPs was removed for LD clumping. We identified novel GxEs using 
the reference set; all the identified interactions were confirmed using the replication 




2.1. Identification of Gene-by-Obesity Interactions on TG Levels 
We conducted GWISs for gene-by-obesity interactions on quantitative lipid levels in 
Supplemental Table S11. We compared the identified GxE loci of TG with the results 
from our previous study in Table 8; we newly found four genetic markers located on 
APOA5 and BUD13 interacting with BMI. They had strong marginal genetic effects 
on TG: rs2075291 (P=3.52x10-76) and rs651821 (P=2.42x10-140) located on APOA5, 
rs2000571 (P=9.70x10-25) and rs2041967 (P=6.59x10-31) located on BUD13. Except 
for rs2041967 (r2=0.20), all the detected SNPs were in LD (r2≥0.50) with the variant 
reported in our previous study, rs1558860 near BUD13. Unfortunately, we could not 
find any genetic interactions with WC or WHR on quantitative TG levels. Genomic 
inflation factors (λ) of marginal, main SNP, and interactive effects on TG levels were 
suggested in Supplemental Table S12. 
 
Compared with the result from our research on dyslipidemia, directions of marginal 
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and main SNP effects were consistent with directions of ORD and ORG; on the other 
hand, those of GxE effects were inconsistent with those of ORGxE (Table 8). BUD13 
marked by rs2041967, for example, showed synergistic effects with BMI on the risk 
of abnormal TG; the ORGxE was 1.11 (P=2.03x10-1). For the genetic interaction with 
BMI on TG levels, however, the GxE effect was estimated to be 0.03 (P=2.03x10-1) 
in the opposite direction. Conversely, BUD13 marked by rs1558860 had antagonistic 
effects with BMI on the risk of abnormal TG elevation; the ORGxE was estimated to 
be 0.80 (P=3.27x10-3). For BUD13-by-BMI interactions on TG levels, however, the 
GxE effect was estimated to be 0.02 (P=1.46x10-1) in the opposite direction. 
 
2.2. Identification of Gene-by-Lifestyle Interactions on SBP Levels 
We also carried out GWISs for gene-by-lifestyle interactions on continuous BP levels 
in Supplemental Table S13. We compared the identified GxE variants of BP with the 
results from our previous study on the risk of HBP in Table 9; we focused on genetic 
interactions with alcohol consumption, such as low-risk drinking or heavy drinking. 
As described in Table 9, we identified a novel variant near BTF3P13 interacting with 
heavy drinking to modify quantitative SBP levels; the novel SNP of SBP located on 
BTF3P13 was rs12501917 (P=1.75x10-8). We could not find any genetic interactions 
with low-risk drinking on quantitative SBP levels. Genomic inflation factors (λ) were 
suggested in Supplemental Table S14; we estimated those of genetic effects on SBP 
levels due to marginal associations, main SNPs, and gene-by-lifestyle interactions. 
 
Compared with our previous findings, the directions of marginal genetic effects were 
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completely consistent with those of ORD; on the other hand, directions of main SNP 
and interactive effects were inconsistent with those of ORG and ORGxE. For example, 
ALDH2 marked by rs112605264 showed a consistent trend in the directions of each 
effect. The ORD, ORG, and ORGxE were 1.05 (P=6.68x10-2), 1.03 (P=3.00x10-1), and 
1.41 (P=5.48x10-13); the marginal, main SNP, and interactive effects were estimated 
to be 0.27 (P=1.37x10-1), 0.22 (P=2.57x10-1), and 0.42 (P=4.50x10-1), respectively. 
On the contrary, SH2B3 marked by rs11065905 showed synergistic effects with low-
risk drinking on HBP-S1 risk; the ORGxE was 1.46 (P=3.84x10-8). For the interaction 
with low-risk drinking on SBP, the GxE effect was 0.19 (P=7.92x10-1) in the opposite 




We conducted two independent GxE studies at a genome-wide scale: 1) a GWIS for 
gene-by-obesity interactions on quantitative lipid levels and 2) a GWIS for gene-by-
lifestyle interactions on quantitative BP levels. We evaluated whether the differences 
in scales of outcome variables (continuous vs. dichotomous) had affected the results 
of our previous studies. In GWISs for quantitative TG scales, we newly detected four 
interactions of BMI with APOA5 or BUD13. All the genetic variants were in LD with 
the findings from our previous studies, except for rs2041967 (r2=0.20); we could not 
find any interactions due to WC or WHR. In GWISs for quantitative SBP scales, on 
the other hand, we identified only one SNP on TSPAN5 at the standard genome-wide 
significance level; there were no gene-by-lifestyle interactions on quantitative DBP. 
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Even though we found fewer GxE variants of dyslipidemia or hypertension by using 
quantitative scales of outcome variables, this study is meaningful in that it extended 
some analytical GxE approaches to quantitative outcomes and compared the results 
between two different outcome scales. As reported in the earlier simulation study on 
the statistical power of detecting GxEs (30), CO analyses and any derivatives of CO 
tests, such as EB, CT1, and CT2, are optimized to test genetic variants having a weak 
marginal effect. We also ascertained that the direction of each genetic effect, such as 
the marginal, main SNP, and gene-by-lifestyle interactive effect, was estimated to be 
consistent regardless of the scales of outcome variables. 
 
In the GWISs for dyslipidemia and HBP, we used dichotomous outcomes instead of 
using quantitative scales of outcomes because the following reasons would improve 
the statistical power. 1) Some analytical methods for testing GxEs use dichotomous 
traits as a prerequisite, such as CO and EB tests, and these analyses are optimized to 
identify genetic variants having weak marginal effects. 2) Some approaches, such as 
CC, DG2, EG2, H2, and EDGxE approaches, could be extended to continuous scales 
of outcomes, and these methods provide more power for SNPs with strong marginal 
effects (30). 3) In analyses of statistical interactions, quantitative scales are sensitive 
to distribution; it is well-known that some non-normal distribution may generate type 
1 errors or false-positive results of interactions. 
 
Actually, our approaches using dichotomous outcomes could cover the broader range 
of gene-by-obesity and gene-by-lifestyle interactive variants, having strong marginal 
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effects as well as weak marginal effects, than the GWISs using quantitative scales of 
TG and SBP (Table 8 and 9). Moreover, GWISs using dichotomous scales were even 
more powerful and gave consistent results of GxEs. As recommended in several GxE 
studies (30, 105), it is more important to use multiple analytical methods as possible 
to provide more power and generate consistent results for GxE analyses. 
 
For genetic variants with weak marginal effects, a CO test could be the most intuitive 
approach to detect interactions; it is only valid when the assumption of independence 
between genes and environmental factors is satisfied. Under these assumptions, CO 
analyses provide more power to detect GxEs than the other exhaustive scans or two-
step methods; we can also test potential interactions directly with this approach. For 
variants having moderate to strong marginal effects, an EDGxE method could be the 
most appropriate way to investigate genetic interactions with environmental factors 
at a genome-wide scale. This two-step method ensures sufficient power to find GxEs 











Summary and Conclusions 
 
1. General Discussion 
 
In this study, we investigated the genetic interaction with modifiable lifestyle factors, 
such as cigarette smoking, alcohol consumption, and obesity. We conducted GWISs 
for 1) gene-by-obesity interactions on dyslipidemia, 2) gene-by-lifestyle interactions 
on hypertension, and 3) gene-by-obesity and gene-by-lifestyle interactions on lipids 
and BP levels, respectively. Our GxE study is different from previous genetic studies, 
particularly GWASs, in several points. First of all, we have focused on the estimates 
of effect differences between subgroups stratified by each genetic and environmental 
factor, so-called the GxE effects, not the marginal genetic effects. Secondly, we have 
applied multiple analytical models as possible and verified the results by replications 
and stratified analyses; we have used four Korean genome cohorts formulated on the 
identical research protocol. Finally, we have suggested the additional heritability of 
each lipid and BP attributable to both marginal associations and genetic interactions 
with modifiable environmental factors. 
 
Even though our research has complemented the earlier GWASs on dyslipidemia or 
hypertension, especially in terms of GxEs, there are some inherent limitations in our 
approaches for testing interactions on lipid profiles and BP traits. For genetic factors, 
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we have investigated only GxEs due to a set of common variants; genetic interactions 
due to low-frequency or rare variants (MAF<0.01) were not considered in this study. 
Unfortunately, there was not enough information for low-frequency and rare variants 
in our study populations. By considering the sample size requirement for the analysis 
on GxEs is further inflated to solve the problem of multiple comparisons at genome-
wide levels (15, 105), GWISs based on low-frequency or rare variants require much 
larger sample sizes to detect genetic interactions with environmental factors. Current 
analytical approaches using low-frequency or rare variants, moreover, do not provide 
adequate power for testing interactions; the latest method based on gene-set and the 
sum of powered score analyses also has limitations in finding interactions at variant-
by-variant levels (134, 135). 
 
For environmental factors, on the other hand, the complexity of measuring exposures 
and assigning temporality need to be considered in GxE studies, especially based on 
the CC study design (21, 22). In this study, we determined environmental factors by 
using indirect measures. We decided behavioral traits of cigarette smoking based on 
self-reports; traits of alcohol consumption were also assessed by using a self-reported 
alcohol intake. Obesity traits, in addition, were surrogate measurements of overall or 
abdominal adiposity, such as BMI, WC, and WHR (137). Even though we have used 
repeated measures of each phenotype, environmental factors in this GxE study could 
be relatively unstable than genetic factors; it is hard to consider a fluctuation in each 
exposure, especially in CC studies. Unfortunately, the outcome variable, such as the 
risk of dyslipidemia or hypertension, associated with environmental factors may be 
influenced by not only the estimated exposures themselves but also the source or the 
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place or the temporality of environmental exposures (22). Current analytical models 
need to be improved by considering a mixed model allowing both fixed and random 
effects of environmental factors to clarify the temporality issues. 
 
We have applied emerging analytical models as possible to find interactions between 
genetic and environmental factors at a genome-wide scale. Some methods for GxEs, 
however, were not included in this GWISs: 1) 2-df test (148, 149), 2) 3-df test (150), 
and 3) variance heterogeneity test (151). A 2-df analysis, the combination of DG and 
CC models in chapter II, tests the following joint null hypothesis: λG=βGxE=0. A 3-df 
analysis, the combination of DG, EG, and CC models, tests the following hypothesis: 
λG=δG=βGxE=0. A variance heterogeneity analysis, on the other hand, tests inequality 
of variance between genotypes to prioritize SNPs for further analyses; the prioritized 
variants are tested for GxEs against other genetic or environmental factors (151). All 
the methods, such as 2-df, 3-df, and variance heterogeneity tests, provide differential 
power to detect interactions according to marginal genetic and GxE effects; we may 
find more interactions by applying these analytical methods in future studies. 
 
The suggested analytical models were verified for achieving the nominal type 1 error 
rate, the alpha less than 0.05, and providing sufficient power in the simulation study 
with multiple scenarios (30). However, we did not estimate type 1 error rates and the 
statistical power of each analytical method in our study populations. We selected the 
union of identified SNPs from multiple analytical models for further verification, not 
the intersection of findings. As we did not consider the replication between analytical 
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methods, there could be possible type 1 errors or false-positive findings. We thought 
the possible false-positive findings could be filtered by comparing variants identified 
from the reference set with those from the replication set. To ensure adequate power 
of detecting GxEs, on the other hand, we applied multiple analytical methods, which 
covered a broad range of interactions due to genetic loci with strong marginal effects 
as well as weak marginal effects (Reference Table R2 and Figure R1). 
 
2. Summary and Conclusions 
 
Dyslipidemia and hypertension, one of the most prevalent health-related conditions 
for Koreans, are well-established CVD risk factors. Previous studies on the complex 
traits imply the possible roles of gene-by-obesity or gene-by-lifestyle interactions on 
the risk of dyslipidemia and hypertension. Current GWASs have identified more than 
500 and 800 genetic loci of plasma lipids and BP levels, respectively. The identified 
variants, however, were mainly focused on individuals of European descent and only 
explained a small fraction of the total and genetic variances of each lipid and BP trait. 
Interactions between genetic and environmental factors are believed to be a potential 
source of the missing heritability. Even though GWASs have successfully identified 
dozens of genetic markers related to lipids or BP levels, the interaction structures are 
not well-known. We intended to search lipid-associated or BP-associated genetic loci 
modifying the effect of risk factors, such as cigarette smoking, alcohol consumption, 




In chapter III, we identified 55 SNPs showing genome-wide significant GxE effects 
on the risk of dyslipidemia with at least one of the obesity traits. After LD clumping, 
we identified about 20 gene-by-obesity interactions due to novel variants located on 
SCN1A and SLC12A8; we also detected lipid-associated variants located on APOA5, 
BUD13, ZNF259, and HMGCR, which have been reported in previous GWASs. For 
normal-weight individuals having no risk alleles (low-risk group), HDL-C decreased 
by 0.032 mmol/L (95% CI, 0.030-0.034 mmol/L) for each unit (1 kg/m2) increase in 
BMI; a decrement of HDL-C was 0.039 mmol/L (95% CI, 0.035-0.043 mmol/L) for 
individuals with at least one risk allele (high-risk group) and 0.038 mmol/L (95% CI, 
0.033-0.043 mmol/L) for upper 50% of the high-risk group (higher-risk group). The 
declining trends were far clearer in obese individuals; similarly, we ascertained that 
an increment of TG was different for each genetic subgroup, and the trends of change 
were clearer in individuals with obesity. The genetic contribution, on the other hand, 
was markedly higher when several independent gene-by-obesity interactive variants 
were present for each pair of lipid traits and environmental factors. About 36.6% of 
the TG heritability, for example, was due to 40 independent GWAS-identified SNPs 
only; genetic contributions increased to 47.1% when we considered the interactions 
of APOA5 or BUD13 with WC. For Caucasians, the additional heritability of TG due 
to the genetic interaction with WC was 5.8%; the gain was 10.6% for Koreans. 
 
In chapter IV, we identified 62 SNPs showing genome-wide significant GxE effects 
on the risk of hypertension with lifestyle factors, such as cigarette smoking, alcohol 
consumption, and obesity traits. 24 gene-by-lifestyle interactions remained after LD 
clumping: interactions due to 1) novel variants (BRAP and SH2B3), 2) BP-associated 
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variants (ATP2B1), 3) alcohol-associated variants (ALDH2, CUX2, HECTD4, MYL2, 
OAS3), and 4) obesity-related variants (ST5). The genetic contribution, on the other 
hand, increased with differences between GWAS-identified and total genetic impacts 
of 0.3-2.1% by considering both marginal associations and genetic interactions with 
cigarette smoking or alcohol consumption, corresponding to 39.3% and 14.6-26.7% 
of the total and SNP-based heritability of HBP-S1, respectively. 
 
In chapter V, we conducted two independent GxE studies for quantitative outcomes: 
1) a GWIS for testing gene-by-obesity interactions on lipid levels and 2) a GWIS for 
testing gene-by-lifestyle interactions on BP levels. In the first study, we detected four 
genetic variants located on APOA5 and BUD13 interacting with BMI. The identified 
variants had strong marginal genetic effects on TG: rs2075291 (p-value=3.52x10-76) 
and rs651821 (p-value=2.42x10-140) on APOA5, rs2000571 (p-value=9.70x10-25) and 
rs2041967 (p-value=6.59x10-31) on BUD13. All the identified SNPs were in LD with 
rs1558860 located on BUD13, which reported in our previous GWISs for the risk of 
abnormal TG elevation, except for rs2041967 (r2=0.20). In the second GWIS, on the 
other hand, we identified a novel genetic variant located on TSPAN5 interacting with 
heavy drinking to modify quantitative SBP levels: rs12501917 (p-value=1.75x10-8). 
We could not detect any gene-by-lifestyle interactions on quantitative DBP levels. 
 
Many human traits or diseases are known to be a consequence of the combined effect 
of genes, environmental factors, and their interactions. Studies on GxEs hold the key 
to further insights on human complex traits and the development of better prediction 
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models for diseases. Our studies on GxEs at a genome-wide scale, so-called GWISs, 
for Koreans revealed novel genetic loci of dyslipidemia and hypertension interacting 
with lifestyle risk factors: cigarette smoking, alcohol consumption, and obesity traits. 
Compared with GWAS-identified loci having marginal effects only, the inclusion of 
GxE SNPs clearly explained more of the total and genetic variances of dyslipidemia 
and hypertension. Based on the different allele frequencies between Caucasians and 
Asians, in addition, Asians experience a higher risk of dyslipidemia, particularly for 
TG, despite a small increase in obesity traits, such as BMI, WC, or WHR. The newly 
identified gene-by-obesity and gene-by-lifestyle interactions can be used to classify 
individuals into higher-risk or lower-risk groups and to personalize health guidelines 
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Table 1. Basic characteristics of the participants in each Korean cohort 
 Total 
Reference Set Replication Set 
Ansan Cohort Ansung Cohort Urban Cohort Rural Cohort 
Participants 16,014 4,236 3,606 3,436 4,736 
Age (Years) 55.2±9.4 50.1±7.7 56.9±8.8 52.7±8.2 60.2±9.3 
Sex, Male (%) 7,075 (44.2) 2,136 (50.4) 1,531 (42.5) 1,494 (43.5) 1,914 (40.4) 
BMI (kg/m2) 24.2±3.0 24.5±2.8 24.4±3.2 23.9±2.9 23.9±3.2 
WC (cm) 82.9±8.7 80.4±7.9 85.6±8.5 82.2±8.8 83.5±8.8 
HC (cm) 93.4±5.9 94.1±4.7 91.0±5.5 95.3±5.8 93.2±6.6 
WHR 0.89±0.07 0.85±0.06 0.94±0.06 0.86±0.06 0.90±0.06 
Total-C (mmol/L)* 5.07±0.87 5.11±0.81 4.87±0.80 5.13±0.88 5.13±0.94 
HDL-C (mmol/L)* 1.23±0.29 1.18±0.24 1.17±0.24 1.42±0.33 1.18±0.29 
LDL-C (mmol/L)* 3.11±0.80 3.18±0.74 2.96±0.72 3.08±0.82 3.20±0.85 
TG (mmol/L)* 1.57±1.01 1.64±0.96 1.63±0.99 1.37±0.98 1.62±1.08 
Remnant-C (mmol/L)* 0.72±0.46 0.75±0.44 0.75±0.45 0.63±0.45 0.74±0.49 
 
LDL-C was calculated using the Friedewald’s formula for individuals with TG under 4.52 mmol/L; Remnant-C was determined as the level of 
Total-C minus HDL-C minus LDL-C. *Plasma levels of lipids were adjusted for age, age2, and sex. Detailed features stratified by obesity status 
into subgroups based on BMI, WC, and WHR are presented in Supplemental Table S2 and S3. 
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Table 2. Novel gene-by-obesity interactive loci modifying the risk of dyslipidemia identified from the meta-analysis of the Korean cohorts 
Trait Environment Gene Marker CHR Position MAF A1/A2 










































































































































Table 2. Continued 
Trait Environment Gene Marker CHR Position MAF A1/A2 











































The results for each gene-by-obesity interaction were summarized according to the discriminators of obesity traits: BMI, WC, and WHR. More 












Environment Gene Marker A1/A2 
Contribution (%) of Genetic Variants 
Contribution of 
GWAS-identified 
Loci for KOR 
(Number of SNPs) 
Additional Contribution of Gene-by-Obesity Interaction 
(Allele Frequency in Each Ethnic Group*) Total Genetic 
Contribution in 








































































































































































































































Environment Gene Marker A1/A2 
Contribution (%) of Genetic Variants 
Contribution of 
GWAS-identified 
Loci for KOR 
(Number of SNPs) 
Additional Contribution of Gene-by-Obesity Interaction 
(Allele Frequency in Each Ethnic Group*) Total Genetic 
Contribution in 






























































Abbreviations for each ethnic group are as follows: Korean (KOR), East Asian (EAS), South Asian (SAS), European (EUR), American (AMR), 







Table 4. Basic characteristics of the participants in each Korean cohort 
 Total 
Reference Set Replication Set 
Ansan Cohort Ansung Cohort Urban Cohort Rural Cohort 
Participants 15,954 4,256 3,680 3,319 4,699 
Age (Years) 55.1±9.4 50.0±7.6 56.7±8.7 52.5±8.1 60.2±9.3 
Sex, Male (%) 7,037 (44.1) 2,154 (50.6) 1,568 (42.6) 1,420 (42.8) 1,895 (40.3) 
BMI (kg/m2) 24.2±3.1 24.5±2.9 24.4±3.3 23.9±2.9 23.9±3.1 
WC (cm) 82.9±8.7 80.5±7.9 85.6±8.5 82.1±8.7 83.4±8.7 
HC (cm) 93.4±5.9 94.2±4.8 91.0±5.6 95.3±5.8 93.1±6.6 
WHR 0.89±0.07 0.85±0.06 0.94±0.06 0.86±0.06 0.90±0.06 
SBP (mmHg)* 121.2±14.7 117.6±14.0 126.8±15.1 121.3±13.4 120.0±14.4 
DBP (mmHg)* 79.2±9.5 79.1±9.6 83.6±8.7 76.9±9.4 77.3±8.9 
MAP (mmHg)* 93.2±10.6 91.9±10.6 98.0±10.3 91.7±10.1 91.5±10.0 
PP (mmHg)* 42.0±9.5 38.4±7.9 43.2±9.8 44.4±8.7 42.7±10.2 
Mid-BP (mmHg)* 100.2±11.4 98.4±11.4 105.2±11.3 99.1±10.7 98.7±10.9 
 
We defined MAP as the sum of DBP and PP divided by three. PP was determined as the level of SBP minus DBP. Mid-BP was the average of 




Table 5. Novel gene-by-lifestyle interactive loci modifying the risk of hypertension identified from the meta-analysis of the Korean cohorts 
Trait Environment Gene Marker CHR Position MAF A1/A2 


















































































































































Table 5. Continued 
Trait Environment Gene Marker CHR Position MAF A1/A2 









































































Based on WHR 









The results for each gene-by-lifestyle interaction were summarized according to the behavioral traits of cigarette smoking, alcohol consumption, 










Environment Gene Marker A1/A2 
Contribution (%) of Genetic Variants 
Contribution of 
GWAS-identified 
Loci for KOR 
(Number of SNPs) 
Additional Contribution of Gene-by-Lifestyle Interaction 
(Allele Frequency in Each Ethnic Group*) Total Genetic 
Contribution in 



































































































































































































































Environment Gene Marker A1/A2 
Contribution (%) of Genetic Variants 
Contribution of 
GWAS-identified 
Loci for KOR 
(Number of SNPs) 
Additional Contribution of Gene-by-Lifestyle Interaction 
(Allele Frequency in Each Ethnic Group*) Total Genetic 
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Based on WHR 















Abbreviations for each ethnic group are as follows: Korean (KOR), East Asian (EAS), South Asian (SAS), European (EUR), American (AMR), 





Table 7. Basic characteristics of the participants in each Korean cohort for quantitative GxE analyses 
 
a. Basic characteristics of the participants in each Korean cohort for gene-by-obesity interaction study on quantitative lipid levels 
 Total 
Reference Set Replication Set 
Ansan Cohort Ansung Cohort Urban Cohort Rural Cohort 
Participants 15,754 4,141 3,533 3,353 4,727 
Age (Years) 55.2±9.5 50.0±7.6 56.8±8.8 52.6±8.2 60.2±9.3 
Sex, Male (%) 6,973 (44.3) 2,096 (50.6) 1,508 (42.7) 1,461 (43.6) 1,908 (40.4) 
BMI (kg/m2) 24.2±3.0 24.5±2.8 24.4±3.2 23.9±2.9 23.9±3.2 
WC (cm) 82.8±8.7 80.4±7.9 85.5±8.4 82.2±8.7 83.5±8.8 
HC (cm) 93.4±5.9 94.1±4.7 90.9±5.5 95.3±5.8 93.2±6.6 
WHR 0.89±0.07 0.85±0.06 0.94±0.06 0.86±0.06 0.90±0.06 
Total-C (mmol/L)* 5.06±0.87 5.09±0.80 4.86±0.78 5.13±0.88 5.13±0.94 
HDL-C (mmol/L)* 1.23±0.29 1.18±0.24 1.17±0.24 1.42±0.33 1.18±0.29 
LDL-C (mmol/L)* 3.11±0.80 3.17±0.73 2.95±0.72 3.08±0.81 3.20±0.85 
TG (mmol/L)* 1.57±1.00 1.63±0.94 1.62±0.95 1.36±0.97 1.62±1.08 




Table 7. Continued 
 
b. Basic characteristics of the participants in each Korean cohort for gene-by-lifestyle interaction study on quantitative BP levels 
 Total 
Reference Set Replication Set 
Ansan Cohort Ansung Cohort Urban Cohort Rural Cohort 
Participants 15,954 4,256 3,680 3,319 4,699 
Age (Years) 55.1±9.4 50.0±7.6 56.7±8.7 52.5±8.1 60.2±9.3 
Sex, Male (%) 7,037 (44.1) 2,154 (50.6) 1,568 (42.6) 1,420 (42.8) 1,895 (40.3) 
BMI (kg/m2) 24.2±3.1 24.5±2.9 24.4±3.3 23.9±2.9 23.9±3.1 
WC (cm) 82.9±8.7 80.5±7.9 85.6±8.5 82.1±8.7 83.4±8.7 
HC (cm) 93.4±5.9 94.2±4.8 91.0±5.6 95.3±5.8 93.1±6.6 
WHR 0.89±0.07 0.85±0.06 0.94±0.06 0.86±0.06 0.90±0.06 
SBP (mmHg)* 121.2±14.7 117.6±14.0 126.8±15.1 121.3±13.4 120.0±14.4 
DBP (mmHg)* 79.2±9.5 79.1±9.6 83.6±8.7 76.9±9.4 77.3±8.9 
MAP (mmHg)* 93.2±10.6 91.9±10.6 98.0±10.3 91.7±10.1 91.5±10.0 
PP (mmHg)* 42.0±9.5 38.4±7.9 43.2±9.8 44.4±8.7 42.7±10.2 




Table 8. Comparison of the identified gene-by-obesity interactions on dyslipidemia defined in dichotomous and quantitative TG scales 
Environment Gene Marker CHR Position MAF A1/A2 
GWIS for Dyslipidemia GWIS for Quantitative TG 





























































































We conducted additional analyses for testing gene-by-obesity interactions using quantitative TG levels as outcome variables. For this analysis, 
we transformed quantitative TG levels into a logarithmic scale; it is known that some non-normal distribution would generate false interactions. 
We identified novel GxE variants using the reference set consisting of the Ansan and Ansung cohorts; all the results were confirmed using the 





Table 9. Comparison of the identified gene-by-lifestyle interactions on hypertension defined in dichotomous and quantitative SBP scales 
Environment Gene Marker CHR Position MAF A1/A2 
GWIS for Hypertension GWIS for Quantitative SBP 























































































































We carried out additional analyses for detecting gene-by-lifestyle interactions, especially genetic interactions with alcohol consumption, using 
quantitative SBP and DBP levels as outcome variables. We identified novel GxE loci using the reference set consisting of the Ansan and Ansung 
cohorts; all the results were confirmed using the replication set composed of the urban and rural cohorts. *The p-value of significance represents 




Table 9. Continued 
Environment Gene Marker CHR Position MAF A1/A2 
GWIS for Hypertension GWIS for Quantitative SBP 





























































































































Figure 1. Gene-by-obesity interactive effects on the risk of dyslipidemia. The bar plots on the lower side of each graph describe the OR as 
the ratio of the probability of dyslipidemia occurring in each exposed group (G≠0 or E≠0) to the probability in a non-exposed group (G=0 and 
E=0). The upper plots, on the other hand, show multiplicative effects of obesity traits for each genetic group. The figures describe the estimated 
dyslipidemia OR due to interactions between (a) HMGCR and abdominal obesity based on WHR, (b) LOC101928271 and overweight class 1, 
(c) BUD13 and abdominal obesity class 1, (d) BUD13 and abdominal obesity class 2, (e) LOC101929680/SCN1A and obesity, (f) APOA5 and 














Figure 2. Changes in plasma lipid levels due to the increments in BMI for each risk group. The study population was classified into three 
groups by the number of risk alleles on gene-by-obesity interactive markers: the low-risk group (individuals with no risk alleles), the high-risk 
group (individuals with at least one risk allele), and the higher-risk group (the upper 50% of individuals belong to the high-risk group). Figures 
above describe the trends of plasma lipid levels due to an increment of 1 kg/m2 in BMI for each group. (a) The differences in the decrement of 
HDL-C for each genetic group were far clearer in the obese group than in the group with normal BMI. (b) The differences in the increment of 












Figure 3. Contributions of marginal associations and gene-by-obesity interactions to the risk of dyslipidemia. The pie plots describe the 
proportion of phenotypic variation attributable to the overall genetic variation (total heritability), genetic markers assayed by SNP arrays (SNP-
based heritability), and the combined set of both GWAS-identified and novel GxE variants. The bar plots, on the other hand, show the proportion 
of genetic variation explained by marginal genetic and gene-by-obesity interactive effects. Figures (a) to (c) describe the genetic contributions 
to abnormal TG attributable to the interaction between genes and obesity traits classified by (a) BMI, (b) WC, and (c) WHR. Figure (d) describes 
the contributions to abnormal Remnant-C attributable to the interaction between genes and obesity traits classified by WHR; further details are 






























Figure 4. Gene-by-Lifestyle interactive effects on the risk of hypertension. The bar plots on the lower side of each graph show ORs as the 
ratio of hypertension probability occurring in each exposed group (G≠0 or E≠0) to the probability in a non-exposed group (G=0 and E=0). The 
upper plots, on the other hand, describe multiplicative effects of lifestyle factors for each genetic group. The figure above shows estimated ORs 
of HBP-S1 or HBP-S2 attributable to the interplay between (a) DCC and ever smoking, (b) RPH3A and low-risk drinking, (c) MYL2 and heavy 
drinking, (d) KLF4 and moderate drinking, (e) RP11-981P6.1 and obesity, (f) ATP2B1 and abdominal obesity class 1, (g) MYL2 and abdominal 














Figure 5. Contributions of marginal associations and gene-by-lifestyle interactions to the risk of hypertension. The pie plots describe the 
proportion of phenotypic variation attributable to the overall genetic variation (total heritability), genetic markers assayed by SNP arrays (SNP-
based heritability), and the combined set of both GWAS-identified and novel GxE variants. The bar plots, on the other hand, show the proportion 
of genetic variation explained by marginal genetic and gene-by-lifestyle interactive effects. Figure (a) and (b) describe the genetic contributions 
to HBP-S1 attributable to the interaction between genes and alcohol consumption. Figure (c) and (d) show the contributions to HBP-S2 due to 





























Supplemental Table S1. Definitions of outcome variables and environmental factors 
a. Clinical thresholds for outcome variables 
Outcome Variable Trait Definition 
Dyslipidemia 
Abnormal Total-C Total-C≥6.21 mmol/L 
Abnormal HDL-C HDL-C≤1.03 mmol/L (for males) or 1.29 mmol/L (for females), the lowest quintile (20%)* 
Abnormal LDL-C LDL-C≥4.14 mmol/L 
Abnormal TG TG≥2.26 mmol/L 
Abnormal Remnant-C the highest quintile (20%) 
Hypertension 
HBP-S1 130≤SBP<140 mmHg or 80≤DBP<90 mmHg 
HBP-S2 SBP≥140 mmHg or DBP≥90 mmHg 
 
*For HDL-C, we used the lowest quintile as a cut-off point because the clinical cut-off points (HDL-C≤1.03 mmol/L for males or 1.29 mmol/L 






Supplemental Table S1. Continued 
b. Clinical thresholds for environmental factors 
Environmental Factor Trait Definition 
Alcohol Consumption 
Moderate Drinking Alcohol Intake≤28.0 g/day (for males) or 14.0 g/day (for females) 
Low-Risk Drinking 28.0<Alcohol Intake≤56.0 g/day (for males) or 14.0<Alcohol Intake≤28.0 g/day (for females) 
Heavy Drinking Alcohol Intake>56.0 g/day (for males) or 42.0 g/day (for females) 
Binge Drinking Alcohol Intake≥70.0 g/day (for males) or 56.0 g/day (for females) 
Obesity 
Underweight BMI<18.5 kg/m2 
Overweight Class 1 BMI≥23.0 kg/m2 
Overweight Class 2 BMI≥25.0 kg/m2 
Obesity BMI≥30.0 kg/m2 
Abdominal Obesity 
Abdominal Obesity Class 1 WC>90 cm (for males) or 80 cm (for females) 
Abdominal Obesity Class 2 WC>102 cm (for males) or 88 cm (for females) 






Supplemental Table S2. Basic characteristics of the participants in the combined Korean cohort 
 Total 
Obesity Based on BMI Abdominal Obesity (WC) Abdominal Obesity (WHR) 
BMI<18.5 18.5-23.0 23.0-25.0 25.0-30.0 30.0≤BMI Normal Class 1 Class 2 Normal Obese 
Participants (%) 16,014 360 (2.2) 5,349 (33.4) 4,265 (26.6) 5,451 (34.0) 589 (3.7) 9,615 (60.0) 4,285 (26.8) 2,114 (13.2) 7,029 (43.9) 8,985 (56.1) 
Age (Years) 55.2±9.4 61.2±10.6 55.7±10.1 54.6±9.1 54.8±8.9 55.0±8.6 54.0±9.6 56.2±9.0 58.8±8.4 52.3±9.1 57.4±9.1 
Sex, Male (%) 7,075 (44.2) 193 (53.6) 2,365 (44.2) 1,894 (44.4) 2,470 (45.3) 153 (26.0) 5,417 (56.3) 1,575 (36.8) 83 (3.9) 3,394 (48.3) 3,681 (41.0) 
BMI (kg/m2) 24.2±3.0 17.6±0.9 21.3±1.2 24.0±0.6 26.7±1.3 31.8±1.8 22.8±2.3 25.6±2.3 27.8±2.9 22.9±2.7 25.2±3.0 
WC (cm) 82.9±8.7 68.8±5.6 76.4±6.2 82.6±5.6 88.7±6.2 98.1±7.7 78.2±6.6 87.7±5.5 94.4±5.4 77.0±6.8 87.4±7.1 
HC (cm) 93.4±5.9 83.5±4.6 89.3±4.4 93.3±3.9 96.9±4.4 104.1±5.8 91.2±5.0 95.9±5.2 98.4±6.3 92.9±5.7 93.8±6.1 
WHR 0.89±0.07 0.82±0.06 0.86±0.07 0.89±0.06 0.92±0.06 0.94±0.07 0.86±0.06 0.92±0.05 0.96±0.06 0.83±0.05 0.93±0.05 
Total-C (mmol/L) 5.07±0.88 4.61±0.85 4.92±0.86 5.10±0.88 5.19±0.88 5.31±0.91 4.97±0.86 5.15±0.89 5.31±0.90 4.97±0.85 5.14±0.90 
Adjusted Total-C 5.07±0.87 4.63±0.84 4.93±0.85 5.10±0.87 5.18±0.87 5.27±0.91 5.01±0.86 5.12±0.88 5.21±0.90 5.01±0.84 5.11±0.89 
HDL-C (mmol/L) 1.23±0.30 1.38±0.36 1.31±0.32 1.22±0.28 1.16±0.26 1.16±0.26 1.26±0.31 1.18±0.27 1.17±0.25 1.29±0.32 1.18±0.27 
Adjusted HDL-C 1.23±0.29 1.40±0.35 1.31±0.31 1.22±0.28 1.16±0.26 1.14±0.26 1.27±0.31 1.18±0.27 1.15±0.25 1.29±0.31 1.18±0.27 
LDL-C (mmol/L) 3.11±0.81 2.71±0.79 3.00±0.78 3.15±0.81 3.21±0.82 3.27±0.84 3.04±0.79 3.18±0.83 3.33±0.82 3.06±0.78 3.16±0.83 
Adjusted LDL-C 3.11±0.80 2.72±0.76 3.01±0.76 3.15±0.80 3.21±0.82 3.22±0.83 3.08±0.79 3.15±0.82 3.20±0.82 3.09±0.78  3.13±0.82* 
TG (mmol/L) 1.57±1.03 1.14±0.70 1.33±0.86 1.58±1.04 1.80±1.09 1.95±1.34 1.47±0.99 1.73±1.10 1.75±0.97 1.36±0.87 1.74±1.11 
Adjusted TG 1.57±1.01 1.12±0.71 1.33±0.85 1.58±1.02 1.79±1.07 2.00±1.32 1.43±0.97 1.75±1.07 1.86±0.96 1.36±0.86 1.74±1.09 
Remnant-C (mmol/L) 0.72±0.47 0.52±0.32 0.61±0.39 0.73±0.48 0.82±0.50 0.89±0.61 0.67±0.45 0.79±0.50 0.80±0.44 0.62±0.40 0.80±0.51 
Adjusted Remnant-C 0.72±0.46 0.51±0.32 0.61±0.39 0.72±0.47 0.82±0.49 0.91±0.60 0.66±0.45 0.80±0.49 0.85±0.44 0.62±0.39 0.80±0.50 
* p-value=6.25x10-3 
Differences between the means for obesity subgroups stratified by BMI, WC, and WHR were examined by the F-test (ANOVA) for continuous 
values and the chi-square test for categorical values; all results were significant (p-value<0.005). Plasma levels of each lipid were adjusted for 
age, age2, and sex. LDL-C was calculated using the Friedewald’s formula for individuals with TG under 4.52 mmol/L; Remnant-C was defined 






Supplemental Table S3. Basic characteristics of the participants in each Korean cohort 
a. Basic characteristics of the participants in the Ansan cohort 
 Total 
Obesity Based on BMI Abdominal Obesity (WC) Abdominal Obesity (WHR) 
BMI<18.5 18.5-23.0 23.0-25.0 25.0-30.0 30.0≤BMI Normal Class 1 Class 2 Normal Obese 
Participants (%) 4,236 42 (1.0) 1,219 (28.8) 1,223 (28.9) 1,601 (37.8) 151 (3.6) 3,218 (76.0) 818 (19.3) 200 (4.7) 2,799 (66.1) 1,437 (33.9) 
Age (Years) 50.1±7.7 51.4±10.0 49.3±7.3 49.9±7.6 50.7±7.8 51.9±8.5 49.2±7.2 52.4±8.1 55.7±9.1 48.6±6.7 53.1±8.4 
Sex, Male (%) 2,136 (50.4) 23 (54.8) 573 (47.0) 637 (52.1) 856 (53.5) 47 (31.1) 1,810 (56.2) 316 (38.6) 10 (5.0) 1,347 (48.1) 789 (54.9) 
BMI (kg/m2) 24.5±2.8 17.8±0.7 21.4±1.1 24.0±0.6 26.7±1.3 31.7±1.9 23.6±2.2 27.0±2.0 29.7±3.0 23.6±2.5 26.3±2.6 
WC (cm) 80.4±7.9 65.2±3.8 73.4±5.4 79.6±4.9 85.5±5.5 94.1±6.4 77.9±6.6 87.3±5.5 93.3±4.8 76.9±6.3 87.4±5.7 
HC (cm) 94.1±4.7 84.6±2.8 90.0±3.1 93.5±2.7 97.1±3.2 104.2±4.5 92.8±3.9 97.7±3.9 101.8±5.5 93.3±4.4 95.7±4.9 
WHR 0.85±0.06 0.77±0.04 0.82±0.06 0.85±0.05 0.88±0.05 0.90±0.05 0.84±0.06 0.89±0.05 0.92±0.04 0.82±0.05 0.91±0.04 
Total-C (mmol/L) 5.11±0.82 4.56±0.87 4.93±0.77 5.14±0.81 5.22±0.82 5.33±0.97 5.05±0.80 5.25±0.81 5.47±1.00 5.02±0.80 5.29±0.83 
Adjusted Total-C 5.11±0.81 4.57±0.86 4.95±0.75 5.14±0.80 5.20±0.81 5.32±0.95 5.07±0.79 5.21±0.80 5.41±0.98 5.05±0.79 5.23±0.83 
HDL-C (mmol/L) 1.18±0.24 1.38±0.31 1.27±0.25 1.18±0.23 1.12±0.22 1.12±0.22 1.20±0.25 1.12±0.21 1.15±0.24 1.22±0.25 1.12±0.21 
Adjusted HDL-C 1.18±0.24 1.39±0.31 1.26±0.25 1.18±0.22 1.13±0.22 1.10±0.22 1.20±0.24 1.12±0.21 1.11±0.24 1.21±0.25 1.12±0.21 
LDL-C (mmol/L) 3.18±0.75 2.69±0.73 3.06±0.70 3.22±0.75 3.25±0.77 3.22±0.81 3.14±0.74 3.26±0.77 3.42±0.85 3.14±0.72 3.25±0.79 
Adjusted LDL-C 3.18±0.74 2.70±0.72 3.07±0.68 3.22±0.74 3.24±0.76 3.19±0.80 3.16±0.73 3.22±0.76 3.33±0.83 3.16±0.71  3.21±0.79* 
TG (mmol/L) 1.64±0.98 1.06±0.30 1.34±0.79 1.61±0.92 1.85±1.04 2.18±1.50 1.55±0.92 1.88±1.14 1.98±1.09 1.45±0.81 2.00±1.18 
Adjusted TG 1.64±0.96 1.03±0.43 1.36±0.78 1.61±0.90 1.83±1.01 2.24±1.48 1.54±0.89 1.91±1.09 2.11±1.09 1.48±0.79 1.95±1.16 
Remnant-C (mmol/L) 0.75±0.45 0.48±0.14 0.61±0.36 0.74±0.42 0.85±0.48 1.00±0.68 0.71±0.42 0.86±0.52 0.91±0.50 0.67±0.37 0.91±0.54 
Adjusted Remnant-C 0.75±0.44 0.47±0.20 0.62±0.36 0.74±0.41 0.84±0.46 1.03±0.68 0.71±0.41 0.87±0.50 0.97±0.50 0.68±0.36 0.89±0.53 
* p-value=2.54x10-2 
Differences between the means for obesity subgroups stratified by BMI, WC, and WHR were examined by the F-test (ANOVA) for continuous 
values and the chi-square test for categorical values; all results were significant (p-value<0.005). Plasma levels of each lipid were adjusted for 
age, age2, and sex. LDL-C was calculated using the Friedewald’s formula for individuals with TG under 4.52 mmol/L; Remnant-C was defined 





Supplemental Table S3. Continued 
b. Basic characteristics of the participants in the Ansung cohort 
 Total 
Obesity Based on BMI Abdominal Obesity (WC) Abdominal Obesity (WHR) 
BMI<18.5 18.5-23.0 23.0-25.0 25.0-30.0 30.0≤BMI Normal Class 1 Class 2 Normal Obese 
Participants (%) 3,606 97 (2.7) 1,119 (31.0) 902 (25.0) 1,301 (36.1) 187 (5.2) 1,642 (45.5) 1,074 (29.8) 890 (24.7) 534 (14.8) 3,072 (85.2) 
Age (Years) 56.9±8.8 61.4±8.2 58.0±9.2 56.5±8.7 56.0±8.4 55.7±8.3 56.4±9.2 56.0±8.7 58.7±7.9 54.8±9.8 57.2±8.6 
Sex, Male (%) 1,531 (42.5) 65 (67.0) 582 (52.0) 370 (41.0) 474 (36.4) 40 (21.4) 1,139 (69.4) 371 (34.5) 21 (2.4) 357 (66.9) 1,174 (38.2) 
BMI (kg/m2) 24.4±3.2 17.5±0.8 21.3±1.2 24.0±0.6 26.8±1.3 31.7±1.7 22.2±2.3 25.2±2.2 27.6±2.7 21.3±2.4 24.9±3.0 
WC (cm) 85.6±8.5 69.5±4.5 78.4±4.9 84.8±4.6 91.2±5.2 100.8±6.2 79.3±6.0 87.6±5.4 94.7±5.5 75.0±5.5 87.4±7.5 
HC (cm) 91.0±5.5 80.4±3.2 86.7±3.4 90.5±3.1 94.3±3.6 101.3±4.3 87.7±4.3 92.3±4.3 95.4±4.9 87.7±5.2 91.5±5.3 
WHR 0.94±0.06 0.86±0.05 0.90±0.05 0.94±0.05 0.97±0.05 1.00±0.05 0.90±0.05 0.95±0.04 0.99±0.04 0.86±0.03 0.95±0.05 
Total-C (mmol/L) 4.87±0.82 4.30±0.75 4.69±0.74 4.88±0.87 5.04±0.80 5.13±0.75 4.66±0.78 4.94±0.81 5.19±0.78 4.50±0.69 4.94±0.82 
Adjusted Total-C 4.87±0.80 4.36±0.74 4.72±0.72 4.88±0.85 5.02±0.78 5.06±0.77 4.76±0.78 4.92±0.80 5.04±0.78 4.62±0.70 4.92±0.80 
HDL-C (mmol/L) 1.17±0.24 1.29±0.31 1.24±0.25 1.17±0.24 1.11±0.21 1.12±0.22 1.21±0.26 1.13±0.22 1.13±0.21 1.25±0.27 1.15±0.23 
Adjusted HDL-C 1.17±0.24 1.29±0.31 1.24±0.25 1.17±0.24 1.11±0.21 1.12±0.21 1.22±0.26 1.13±0.22 1.13±0.21 1.26±0.27 1.15±0.23 
LDL-C (mmol/L) 2.96±0.75 2.47±0.66 2.82±0.71 2.96±0.77 3.09±0.74 3.13±0.79 2.77±0.73 3.01±0.75 3.24±0.70 2.67±0.65 3.01±0.76 
Adjusted LDL-C 2.96±0.72 2.55±0.64 2.86±0.68 2.96±0.74 3.07±0.72 3.05±0.78 2.88±0.72 2.99±0.74 3.06±0.69 2.81±0.65 2.99±0.73 
TG (mmol/L) 1.63±1.00 1.18±0.45 1.38±0.75 1.64±1.05 1.84±1.00 1.91±1.60 1.49±0.97 1.72±1.07 1.77±0.91 1.25±0.55 1.70±1.04 
Adjusted TG 1.63±0.99 1.14±0.45 1.37±0.74 1.64±1.04 1.85±0.99 1.95±1.57 1.43±0.96 1.74±1.04 1.86±0.90 1.20±0.54 1.71±1.03 
Remnant-C (mmol/L) 0.75±0.46 0.54±0.21 0.63±0.34 0.75±0.48 0.84±0.46 0.87±0.73 0.68±0.45 0.79±0.49 0.81±0.42 0.57±0.25 0.78±0.48 







Supplemental Table S3. Continued 
c. Basic characteristics of the participants in the urban cohort 
 Total 
Obesity Based on BMI Abdominal Obesity (WC) Abdominal Obesity (WHR) 
BMI<18.5 18.5-23.0 23.0-25.0 25.0-30.0 30.0≤BMI Normal Class 1 Class 2 Normal Obese 
Participants (%) 3,436 65 (1.9) 1,285 (37.4) 946 (27.5) 1,047 (30.5) 93 (2.7) 2,238 (65.1) 934 (27.2) 262 (7.7) 2,027 (59.0) 1,409 (41.0) 
Age (Years) 52.7±8.2 52.6±9.3 51.8±8.2 52.8±8.1 53.6±8.2 54.5±8.0 51.9±8.1 54.0±8.2 55.3±8.0 51.4±7.8 54.7±8.3 
Sex, Male (%) 1,494 (43.5) 26 (40.0) 453 (35.3) 440 (46.5) 539 (51.5) 36 (38.7) 1,066 (47.6) 404 (43.3) 24 (9.1) 858 (42.3)  636 (45.1)* 
BMI (kg/m2) 23.9±2.9 17.6±0.7 21.4±1.1 24.0±0.6 26.6±1.2 31.8±1.8 22.6±2.2 25.7±2.1 28.2±3.0 22.9±2.5 25.3±2.8 
WC (cm) 82.2±8.8 67.7±5.8 76.1±6.4 82.7±5.6 88.9±6.3 98.5±6.6 78.1±6.8 88.7±5.8 94.7±5.7 78.0±7.3 88.3±7.0 
HC (cm) 95.3±5.8 86.5±4.7 91.5±4.3 95.6±3.8 99.3±4.4 107.3±6.0 93.0±4.7 98.9±4.6 102.6±5.9 94.5±5.5 96.6±6.0 
WHR 0.86±0.06 0.78±0.06 0.83±0.06 0.86±0.05 0.89±0.05 0.92±0.06 0.84±0.06 0.90±0.05 0.92±0.06 0.83±0.05 0.91±0.04 
Total-C (mmol/L) 5.13±0.89 4.83±0.78 5.03±0.88 5.14±0.86 5.22±0.91 5.50±0.94 5.06±0.87 5.22±0.90 5.32±0.99 5.06±0.89 5.22±0.89 
Adjusted Total-C 5.13±0.88 4.86±0.76 5.04±0.85 5.13±0.85 5.21±0.92 5.45±0.94 5.08±0.86 5.20±0.89 5.24±0.99 5.08±0.86 5.19±0.89 
HDL-C (mmol/L) 1.42±0.34 1.66±0.44 1.52±0.36 1.39±0.32 1.32±0.30 1.34±0.33 1.47±0.35 1.33±0.31 1.34±0.30 1.47±0.35 1.34±0.32 
Adjusted HDL-C 1.42±0.33 1.65±0.42 1.50±0.35 1.40±0.31 1.33±0.29 1.34±0.33 1.47±0.34 1.33±0.30 1.29±0.30 1.47±0.34 1.35±0.31 
LDL-C (mmol/L) 3.08±0.83 2.69±0.78 2.98±0.80 3.10±0.84 3.17±0.84 3.36±0.87 3.02±0.81 3.15±0.84 3.31±0.88 3.01±0.82 3.17±0.83 
Adjusted LDL-C 3.08±0.82 2.71±0.74 2.99±0.77 3.10±0.83 3.16±0.84 3.31±0.87 3.04±0.80 3.13±0.83 3.22±0.88 3.03±0.81 3.14±0.83 
TG (mmol/L) 1.37±1.00 1.06±0.95 1.14±0.78 1.41±1.13 1.61±1.06 1.74±0.98 1.27±0.98 1.60±1.08 1.47±0.81 1.25±1.00 1.54±0.99 
Adjusted TG 1.37±0.98 1.09±0.92 1.18±0.78 1.40±1.11 1.57±1.03 1.75±0.93 1.25±0.95 1.60±1.04 1.61±0.80 1.26±0.97 1.53±0.97 
Remnant-C (mmol/L) 0.63±0.46 0.48±0.44 0.52±0.36 0.65±0.52 0.74±0.48 0.80±0.45 0.58±0.45 0.73±0.49 0.67±0.37 0.57±0.46 0.71±0.45 








Supplemental Table S3. Continued 
d. Basic characteristics of the participants in the rural cohort 
 Total 
Obesity Based on BMI Abdominal Obesity (WC) Abdominal Obesity (WHR) 
BMI<18.5 18.5-23.0 23.0-25.0 25.0-30.0 30.0≤BMI Normal Class 1 Class 2 Normal Obese 
Participants (%) 4,736 156 (3.3) 1,726 (36.4) 1,194 (25.2) 1,502 (31.7) 158 (3.3) 2,517 (53.1) 1,459 (30.8) 760 (16.0) 1,669 (35.2) 3,067 (64.8) 
Age (Years) 60.2±9.3 67.2±7.9 61.6±9.8 59.3±9.0 58.9±8.7 57.5±8.5 60.3±9.8 59.8±9.0  60.9±8.3* 58.9±10.0 61.0±8.8 
Sex, Male (%) 1,914 (40.4) 79 (50.6) 757 (43.9) 447 (37.4) 601 (40.0) 30 (19.0) 1,402 (55.7) 484 (33.2) 28 (3.7) 832 (49.9) 1,082 (35.3) 
BMI (kg/m2) 23.9±3.2 17.5±0.9 21.3±1.2 24.0±0.6 26.8±1.3 32.1±1.9 22.2±2.4 25.1±2.3 27.4±3.0 22.3±2.9 24.8±3.0 
WC (cm) 83.5±8.8 69.8±6.2 77.6±6.3 83.9±5.5 89.7±6.1 98.4±9.3 77.9±6.7 87.5±5.4 94.2±5.2 76.7±7.1 87.1±7.3 
HC (cm) 93.2±6.6 83.9±4.7 89.0±5.0 93.5±4.4 97.4±4.9 105.6±6.9 89.9±5.4 95.6±5.1 99.5±6.3 92.0±6.8 93.8±6.4 
WHR 0.90±0.06 0.83±0.06 0.87±0.06 0.90±0.05 0.92±0.06 0.93±0.08 0.87±0.06 0.92±0.05 0.95±0.05 0.83±0.04 0.93±0.05 
Total-C (mmol/L) 5.13±0.96 4.73±0.89 4.98±0.95 5.19±0.93 5.25±0.96 5.41±0.98 4.99±0.94 5.22±0.95 5.40±0.95 4.95±0.90 5.23±0.98 
Adjusted Total-C 5.13±0.94 4.77±0.86 5.00±0.93 5.18±0.91 5.25±0.95 5.34±0.98 5.05±0.93 5.19±0.94 5.26±0.95 5.00±0.88 5.20±0.96 
HDL-C (mmol/L) 1.18±0.29 1.32±0.31 1.23±0.30 1.17±0.28 1.12±0.26 1.13±0.26 1.20±0.30 1.15±0.27 1.17±0.26 1.22±0.30 1.16±0.28 
Adjusted HDL-C 1.18±0.29 1.32±0.31 1.24±0.30 1.17±0.27 1.12±0.26 1.12±0.26 1.21±0.30 1.15±0.27 1.16±0.26 1.23±0.30 1.16±0.27 
LDL-C (mmol/L) 3.20±0.88 2.88±0.85 3.10±0.84 3.26±0.85 3.29±0.92 3.41±0.89 3.10±0.84 3.27±0.90 3.43±0.91 3.10±0.83 3.26±0.90 
Adjusted LDL-C 3.20±0.85 2.90±0.81 3.11±0.81 3.25±0.83 3.29±0.90 3.34±0.90 3.17±0.81 3.24±0.88 3.27±0.91 3.15±0.80 3.23±0.88 
TG (mmol/L) 1.62±1.09 1.17±0.78 1.43±0.99 1.65±1.06 1.83±1.20 1.89±0.95 1.51±1.08 1.74±1.10 1.74±1.03 1.36±0.87 1.76±1.16 
Adjusted TG 1.62±1.08 1.18±0.78 1.43±0.99 1.65±1.04 1.82±1.19 1.93±0.94 1.48±1.07 1.75±1.08 1.83±1.02 1.35±0.86 1.77±1.15 
Remnant-C (mmol/L) 0.74±0.50 0.54±0.36 0.65±0.45 0.75±0.48 0.84±0.55 0.87±0.44 0.69±0.50 0.80±0.51 0.80±0.47 0.62±0.40 0.80±0.53 








Supplemental Table S3. Continued 
e. Basic characteristics of the participants in the Healthy Twin Study 
 Total 
Obesity Based on BMI Abdominal Obesity (WC) Abdominal Obesity (WHR) 
BMI<18.5 18.5-23.0 23.0-25.0 25.0-30.0 30.0≤BMI Normal Class 1 Class 2 Normal Obese 
Participants (%) 3,125 81 (2.6) 1,360 (43.5) 724 (23.2) 869 (27.8) 91 (2.9) 2,127 (68.1) 764 (24.4) 234 (7.5) 1,979 (63.3) 1,146 (36.7) 
Age (Years) 44.1±13.3 37.1±13.5 41.5±12.4 45.7±13.5 47.8±13.4 42.8±13.4 41.5±12.3 48.9±13.4 52.5±14.6 39.8±11.4 51.7±13.1 
Sex, Male (%) 1,259 (40.3) 21 (25.9) 374 (27.5) 350 (48.3) 474 (54.5) 40 (44.0) 931 (43.8) 304 (39.8) 24 (10.3) 766 (38.7)  493 (43.0)* 
BMI (kg/m2) 23.6±3.2 17.7±0.6 21.1±1.2 24.0±0.6 26.8±1.3 32.5±2.3 22.2±2.3 25.8±2.2 29.0±3.2 22.5±2.6 25.6±3.1 
WC (cm) 80.7±9.0 66.4±4.8 74.5±5.5 82.1±5.1 88.7±5.7 100.2±7.4 76.7±6.9 87.6±5.7 95.0±6.8 76.5±7.1 88.0±7.2 
HC (cm) 94.8±5.7 86.5±3.2 91.4±3.7 95.3±3.5 99.1±4.3 108.7±5.1 92.8±4.6 98.0±4.8 102.7±6.3 94.0±5.3 96.2±6.1 
WHR 0.85±0.07 0.77±0.05 0.82±0.06 0.86±0.05 0.90±0.06 0.92±0.05 0.83±0.06 0.89±0.05 0.93±0.05 0.81±0.05 0.91±0.05 
Total-C (mmol/L) 4.90±0.85 4.55±0.79 4.73±0.81 4.93±0.82 5.14±0.87 5.15±0.89 4.79±0.83 5.08±0.83 5.32±0.89 4.77±0.82 5.13±0.85 
Adjusted Total-C 4.90±0.82 4.70±0.77 4.78±0.78 4.90±0.81 5.08±0.86 5.17±0.89 4.82±0.80 5.01±0.82 5.25±0.88 4.83±0.80 5.02±0.85 
HDL-C (mmol/L) 1.31±0.31 1.48±0.31 1.39±0.31 1.28±0.29 1.20±0.27 1.14±0.28 1.35±0.30 1.23±0.30 1.21±0.28 1.36±0.30 1.22±0.30 
Adjusted HDL-C 1.31±0.29 1.43±0.31 1.37±0.30 1.30±0.28 1.23±0.26 1.14±0.27 1.35±0.29 1.24±0.28 1.19±0.28 1.34±0.29 1.25±0.29 
LDL-C (mmol/L) 2.87±0.76 2.46±0.66 2.70±0.70 2.91±0.74 3.13±0.77 3.18±0.86 2.77±0.74 3.05±0.71 3.29±0.85 2.75±0.74 3.09±0.75 
Adjusted LDL-C 2.87±0.73 2.61±0.64 2.75±0.68 2.88±0.72 3.06±0.77 3.20±0.87 2.80±0.71 2.98±0.70 3.23±0.85 2.81±0.72 2.98±0.75 
TG (mmol/L) 1.30±0.88 0.91±0.40 1.03±0.54 1.36±0.94 1.64±0.95 1.99±1.88 1.16±0.76 1.57±1.07 1.65±0.84 1.12±0.73 1.60±1.02 
Adjusted TG 1.30±0.84 1.05±0.38 1.11±0.53 1.31±0.92 1.54±0.92 1.99±1.83 1.16±0.72 1.54±1.03 1.73±0.81 1.16±0.69 1.53±1.00 
Remnant-C (mmol/L) 0.71±0.34 0.61±0.26 0.64±0.29 0.73±0.33 0.82±0.38 0.83±0.51 0.67±0.31 0.80±0.38 0.82±0.39 0.66±0.30 0.82±0.39 








Supplemental Table S4. Gene-by-obesity interactive loci of dyslipidemia obtained from the meta-analysis of the cohorts (before LD clumping) 
Trait Environment Gene Marker CHR Position MAF A1/A2 








Screen Test Cut-Off 







5.13E-09 3.32E-02 5.00E-02 CT1/CT2 







3.90E-09 4.33E-02 5.00E-02 CT1/CT2 







5.50E-09 3.52E-02 5.00E-02 CT1/CT2 







3.80E-09 4.54E-02 5.00E-02 CT1/CT2 







6.29E-09 1.17E-02 5.00E-02 
CT1/CT2 
EDGxE 







4.84E-09 1.14E-02 5.00E-02 
CT1/CT2 
EDGxE 







4.76E-09 1.38E-02 5.00E-02 
CT1/CT2 
EDGxE 







7.91E-09 7.33E-03 1.25E-02 CT1/CT2 







8.39E-09 7.34E-03 1.25E-02 CT1/CT2 







6.68E-09 1.21E-02 5.00E-02 
CT1/CT2 
EDGxE 




















5.54E-09 2.26E-02 5.00E-02 CT1/CT2 
Total-C 
Abdominal Obesity  
Class 1 











Abdominal Obesity  
Class 1 







3.99E-09 2.62E-02 5.00E-02 CT1/CT2 
Total-C 
Abdominal Obesity  
Class 1 







5.77E-09 2.13E-02 5.00E-02 CT1/CT2 
Total-C 
Abdominal Obesity  
Class 1 







3.62E-09 2.73E-02 5.00E-02 CT1/CT2 
Total-C 
Abdominal Obesity  
Class 2 







8.89E-09 1.15E-02 1.25E-02 EDGxE 
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Supplemental Table S4. Continued 
Trait Environment Gene Marker CHR Position MAF A1/A2 








Screen Test Cut-Off 
Total-C 
Abdominal Obesity  
Class 2 











Abdominal Obesity  
Class 2 







6.46E-09 1.41E-02 5.00E-02 CT1/CT2 
Total-C 
Abdominal Obesity  
Class 2 







1.12E-08 1.06E-02 1.25E-02 EDGxE 
Total-C 
Abdominal Obesity  
Class 2 







1.19E-08 1.02E-02 1.25E-02 EDGxE 
Total-C 
Abdominal Obesity  
Class 2 







9.55E-09 1.19E-02 1.25E-02 EDGxE 
Total-C 
Abdominal Obesity  
Class 2 












Based on WHR 











Abdominal Obesity  
Based on WHR 











Abdominal Obesity  
Based on WHR 







1.47E-08 1.06E-02 1.25E-02 CT1/CT2 
Total-C 
Abdominal Obesity  
Based on WHR 











Abdominal Obesity  
Based on WHR 







9.57E-09 1.05E-02 1.25E-02 CT1/CT2 
Total-C 
Abdominal Obesity  
Based on WHR 







1.09E-08 1.15E-02 1.25E-02 CT1/CT2 
Total-C 
Abdominal Obesity  
Based on WHR 







7.15E-09 7.42E-03 5.00E-02 CT1/CT2 
Total-C 
Abdominal Obesity  
Based on WHR 











Abdominal Obesity  
Based on WHR 































2.56E-04 3.13E-04 7.63E-07 CO 
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Supplemental Table S4. Continued 
Trait Environment Gene Marker CHR Position MAF A1/A2 




















































6.00E-05 2.93E-04 7.63E-07 CO 







8.86E-09 6.79E-04 7.81E-04 
CT1/CT2 
EDGxE 











Abdominal Obesity  
Class 2 











Abdominal Obesity  
Class 2 











Abdominal Obesity  
Class 2 











Abdominal Obesity  
Class 2 







1.91E-09 1.22E-02 1.25E-02 EDGxE 
LDL-C 
Abdominal Obesity  
Class 2 











Abdominal Obesity  
Class 2 











Abdominal Obesity  
Class 2 











Abdominal Obesity  
Class 2 











Abdominal Obesity  
Class 2 











Abdominal Obesity  
Based on WHR 







1.25E-09 4.41E-02 5.00E-02 EDGxE 
LDL-C 
Abdominal Obesity  
Based on WHR 







1.36E-09 4.39E-02 5.00E-02 CT1/CT2 
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Supplemental Table S4. Continued 
Trait Environment Gene Marker CHR Position MAF A1/A2 








Screen Test Cut-Off 
LDL-C 
Abdominal Obesity  
Based on WHR 







9.08E-10 4.57E-02 5.00E-02 EDGxE 
LDL-C 
Abdominal Obesity  
Based on WHR 







8.91E-10 2.06E-02 5.00E-02 CT1/CT2 







5.10E-35 7.54E-03 1.25E-02 EDGxE 







4.02E-34 1.10E-02 1.25E-02 EDGxE 





























5.54E-02 3.87E-06 4.66E-11 CO 
TG 
Abdominal Obesity  
Class 1 











Abdominal Obesity  
Class 1 







8.34E-72 1.82E-02 5.00E-02 CT1/CT2 
TG 
Abdominal Obesity  
Class 1 







4.22E-28 1.42E-02 5.00E-02 EDGxE 
TG 
Abdominal Obesity  
Based on WHR 












Based on WHR 







1.60E-36 1.82E-03 1.25E-02 CT1/CT2 
TG 
Abdominal Obesity  
Based on WHR 











Abdominal Obesity  
Based on WHR 











Abdominal Obesity  
Based on WHR 







1.35E-40 2.55E-02 5.00E-02 CT1/CT2 
TG 
Abdominal Obesity  
Based on WHR 







1.63E-35 3.51E-03 1.25E-02 CT1/CT2 
TG 
Abdominal Obesity  
Based on WHR 







1.67E-34 2.79E-03 3.13E-03 CT1/CT2 
133 
 
Supplemental Table S4. Continued 
Trait Environment Gene Marker CHR Position MAF A1/A2 








Screen Test Cut-Off 
TG 
Abdominal Obesity  
Based on WHR 











Abdominal Obesity  
Based on WHR 







1.07E-34 2.39E-03 3.13E-03 CT1/CT2 
TG 
Abdominal Obesity  
Based on WHR 











Abdominal Obesity  
Based on WHR 
APOA5 
ZPR1(ZNF259) 











Abdominal Obesity  
Based on WHR 
APOA5 
ZPR1(ZNF259) 







8.80E-42 2.69E-02 5.00E-02 CT1/CT2 
TG 
Abdominal Obesity  
Based on WHR 
APOA5 
ZPR1(ZNF259) 











Abdominal Obesity  
Based on WHR 











Abdominal Obesity  
Based on WHR 







5.43E-41 2.80E-02 5.00E-02 CT1/CT2 
TG 
Abdominal Obesity  
Based on WHR 











Abdominal Obesity  
Based on WHR 











Abdominal Obesity  
Based on WHR 











Abdominal Obesity  
Based on WHR 







1.58E-36 1.84E-03 1.25E-02 CT1/CT2 
TG 
Abdominal Obesity  
Based on WHR 











Abdominal Obesity  
Based on WHR 











Abdominal Obesity  
Based on WHR 











Abdominal Obesity  
Based on WHR 







1.17E-34 2.52E-03 3.13E-03 CT1/CT2 
TG 
Abdominal Obesity  
Based on WHR 







2.46E-34 2.76E-03 3.13E-03 CT1/CT2 
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Supplemental Table S4. Continued 
Trait Environment Gene Marker CHR Position MAF A1/A2 








Screen Test Cut-Off 
TG 
Abdominal Obesity  
Based on WHR 







6.41E-37 1.27E-03 1.25E-02 
CT1/CT2 
EDGxE 







9.27E-18 4.55E-02 5.00E-02 EDGxE 







1.76E-18 4.88E-02 5.00E-02 EDGxE 
Remnant-C 
Abdominal Obesity  
Class 2 







8.27E-27 1.61E-02 5.00E-02 EDGxE 
Remnant-C 
Abdominal Obesity  
Class 2 







1.53E-27 1.17E-02 1.25E-02 EDGxE 
Remnant-C 
Abdominal Obesity  
Class 2 







3.06E-27 1.64E-02 5.00E-02 EDGxE 
Remnant-C 
Abdominal Obesity  
Based on WHR 







3.05E-25 7.49E-03 1.25E-02 EDGxE 
Remnant-C 
Abdominal Obesity  
Based on WHR 







5.63E-26 4.94E-03 1.25E-02 EDGxE 
Remnant-C 
Abdominal Obesity  
Based on WHR 







2.33E-26 7.06E-03 1.25E-02 EDGxE 
Remnant-C 
Abdominal Obesity  
Based on WHR 







1.47E-26 7.45E-03 1.25E-02 EDGxE 
Remnant-C 
Abdominal Obesity  
Based on WHR 











Abdominal Obesity  
Based on WHR 













Supplemental Table S5. Genomic inflation factors observed in GWISs for dyslipidemia 
Trait Environment 
Marginal Model Gene-by-Environment Interaction Model 
Marginal Main SNP Interactive 
Total-C Obesity 
Overweight Class 1 1.024001 0.995342 0.985151 
Overweight Class 2 1.024476 1.020683 1.001400 
Obesity 1.028280 1.027328 0.954578 
HDL-C Obesity 
Overweight Class 1 1.023527 1.001867 0.992091 
Overweight Class 2 1.026377 1.025426 1.004673 
Obesity 1.030186 1.030663 0.950974 
LDL-C Obesity 
Overweight Class 1 1.036399 1.010773 0.982385 
Overweight Class 2 1.033528 1.015011 1.001400 
Obesity 1.033050 1.032572 0.936654 
TG Obesity 
Overweight Class 1 1.025902 0.999534 0.992555 
Overweight Class 2 1.029233 1.021630 0.993484 
Obesity 1.031140 1.022578 0.970919 
Remnant-C Obesity 
Overweight Class 1 1.021630 0.991628 0.988386 
Overweight Class 2 1.025902 1.013597 1.005610 
Obesity 1.024476 1.018789 0.971833 
* Any inflated results over 1.05 are shown in bold type. 
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Supplemental Table S5. Continued 
Trait Environment 
Marginal Model Gene-by-Environment Interaction Model 
Marginal Main SNP Interactive 
Total-C Abdominal Obesity 
Abdominal Obesity Class 1 1.025426 1.001867 0.994413 
Abdominal Obesity Class 2 1.028280 1.026853 0.986074 
Abdominal Obesity Based on WHR 1.024476 0.998601 1.006547 
HDL-C Abdominal Obesity 
Abdominal Obesity Class 1 1.024001 1.021156 0.995807 
Abdominal Obesity Class 2 1.026377 1.027328 0.991628 
Abdominal Obesity Based on WHR 1.026853 1.004673 0.996738 
LDL-C Abdominal Obesity 
Abdominal Obesity Class 1 1.035441 1.026377 0.979165 
Abdominal Obesity Class 2 1.034006 1.032572 0.982845 
Abdominal Obesity Based on WHR 1.033050 1.007485 0.999067 
TG Abdominal Obesity 
Abdominal Obesity Class 1 1.025426 1.014540 0.975952 
Abdominal Obesity Class 2 1.031617 1.024476 0.993948 
Abdominal Obesity Based on WHR 1.027328 0.995807 0.979624 
Remnant-C Abdominal Obesity 
Abdominal Obesity Class 1 1.020683 1.007954 1.001867 
Abdominal Obesity Class 2 1.023527 1.024951 1.006547 
Abdominal Obesity Based on WHR 1.023052 0.990701 1.011243 
* Any inflated results over 1.05 are shown in bold type. 
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Supplemental Table S6. Effects of the interplay between genes and obesity traits on the risk of dyslipidemia 
 
a. Effects of the interplay between HMGCR and abdominal obesity based on WHR on the risk of abnormal elevation of Total-C 
Abdominal Obesity 
Based on WHR 
Genotype of rs7702895 
GG (95% CI) GA (95% CI) AA (95% CI) 
Normal 1.00 0.72 (0.62-0.84) 0.56 (0.45-0.70) 
Obese 1.12 (0.96-1.31) 1.05 (0.91-1.21) 0.88 (0.74-1.04) 
Multiplicative Effect 1.12 (0.96-1.31) 1.46 (1.28-1.67) 1.57 (1.26-1.95) 
 
b. Effects of the interplay between LOC101928271 and overweight class 1 on the risk of abnormal elevation of LDL-C 
Overweight Class 1 
Genotype of rs11693076 
CC (95% CI) CT (95% CI) TT (95% CI) 
Normal 1.00 0.98 (0.81-1.19) 0.85 (0.52-1.41) 
Obese 1.82 (1.61-2.06) 1.32 (1.14-1.53) 0.85 (0.59-1.24) 




Supplemental Table S6. Continued 
 
c. Effects of the interplay between BUD13 and abdominal obesity class 1 on the risk of abnormal elevation of TG 
Abdominal Obesity 
Class 1 
Genotype of rs918144 
TT (95% CI) TC (95% CI) CC (95% CI) 
Normal 1.00 0.75 (0.67-0.84) 0.47 (0.40-0.56) 
Obese 1.56 (1.40-1.76) 1.27 (1.14-1.41) 1.00 (0.86-1.15) 
Multiplicative Effect 1.56 (1.40-1.76) 1.68 (1.52-1.86) 2.12 (1.76-2.56) 
 
d. Effects of the interplay between BUD13 and abdominal obesity class 2 on the risk of abnormal elevation of Remnant-C 
Abdominal Obesity 
Class 2 
Genotype of rs2075295 
CC (95% CI) CT (95% CI) TT (95% CI) 
Normal 1.00 0.81 (0.76-0.87) 0.61 (0.56-0.67) 
Obese 1.31 (1.17-1.47) 1.15 (1.04-1.27) 1.08 (0.94-1.25) 




Supplemental Table S6. Continued 
 
e. Effects of the interplay between LOC101929680/SCN1A and obesity on the risk of abnormal reduction of HDL-C 
Obesity 
Genotype of rs11890028 
GG (95% CI) GT (95% CI) TT (95% CI) 
Normal 1.00 0.94 (0.86-1.03) 0.77 (0.50-1.20) 
Obese 1.42 (1.22-1.65) 1.87 (1.49-2.34) 4.83 (4.66-5.00) 
Multiplicative Effect 1.42 (1.22-1.65) 1.99 (1.57-2.52) 6.24 (4.03-9.64) 
 
f. Effects of the interplay between APOA5 and abdominal obesity based on WHR on the risk of abnormal elevation of TG 
Abdominal Obesity 
Based on WHR 
Genotype of rs651821 
CC (95% CI) CT (95% CI) TT (95% CI) 
Normal 1.00 2.08 (1.76-2.46) 4.13 (3.37-5.05) 
Obese 2.56 (2.20-2.99) 3.93 (3.39-4.57) 5.73 (4.83-6.80) 




Supplemental Table S6. Continued 
 
g. Effects of the interplay between APOA5 and abdominal obesity based on WHR on the risk of abnormal elevation of Remnant-C 
Abdominal Obesity 
Based on WHR 
Genotype of rs651821 
CC (95% CI) CT (95% CI) TT (95% CI) 
Normal 1.00 1.74 (1.53-1.97) 3.05 (2.61-3.57) 
Obese 2.20 (1.96-2.46) 3.21 (2.88-3.59) 4.51 (3.98-5.11) 









Supplemental Table S7. Changes in HDL-C and TG due to an increment of BMI of 1 kg/m2 for each risk group 
Trait Risk Group 






















Low 13,091 (83.1) -0.023±0.001 - 8,182 (83.1) -0.032±0.002 - 8,390 (83.1) -0.013±0.001 - 4,909 (83.1) -0.004±0.002 - 
High 2,663 (16.9) -0.026±0.002 5.61E-02 1,668 (16.9) -0.039±0.004 7.93E-02 1,709 (16.9) -0.016±0.003 1.11E-01 995 (16.9) -0.014±0.004 7.58E-04 
Higher 1,331 (8.4) -0.027±0.002 1.07E-01 836 (8.5) -0.038±0.005 7.93E-02 862 (8.5) -0.019±0.004 1.11E-01 495 (8.4) -0.017±0.005 7.58E-04 
TG 
Low 14,007 (88.9) 0.072±0.003 - 8,762 (89.0) 0.087±0.005 - 8,939 (88.5) 0.055±0.005 - 5,245 (88.8) 0.034±0.008 - 
High 1,747 (11.1) 0.070±0.007 9.60E-01 1,088 (11.0) 0.054±0.014 6.11E-02 1,160 (11.5) 0.088±0.012 3.06E-03 659 (11.2) 0.080±0.018 7.81E-03 
Higher 875 (5.6) 0.078±0.010 5.92E-01 548 (5.6) 0.081±0.022 6.11E-02 574 (5.7) 0.095±0.019 3.06E-03 327 (5.5) 0.089±0.022 7.81E-03 
 
Individuals were classified into three risk groups based on the number of risk alleles at GxE loci. Individuals with no risk alleles were classified 
into the low-risk group; individuals with at least one risk allele were classified into the high-risk group; the upper 50% of people belong to the 






Supplemental Table S8. Gene-by-lifestyle interactive loci of hypertension obtained from the meta-analysis of the cohorts 
Trait Environment Gene Marker CHR Position MAF A1/A2 








Screen Test Cut-Off 







9.85E-08 4.95E-02 5.00E-02 CT1 







9.85E-08 4.95E-02 5.00E-02 CT2 







9.60E-01 3.34E-09 1.82E-13 CC 







3.20E-17 1.66E-02 7.63E-07 CO 







3.20E-17 1.66E-02 5.00E-02 EDGxE 







2.07E-11 1.89E-02 7.63E-07 CO 







4.47E-10 5.55E-01 7.63E-07 CO 







5.67E-12 4.95E-02 7.63E-07 CO 







1.25E-140 9.18E-03 5.00E-02 CT2 







1.25E-140 9.18E-03 5.00E-02 EDGxE 







5.26E-10 1.17E-01 7.63E-07 CO 







2.06E-12 1.20E-01 7.63E-07 CO 







9.68E-11 3.55E-02 7.63E-07 CO 







2.29E-16 2.05E-02 7.63E-07 CO 







3.32E-18 6.92E-02 7.63E-07 CO 







5.65E-22 1.63E-02 5.00E-02 EDGxE 







1.38E-27 1.70E-02 5.00E-02 EDGxE 
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Supplemental Table S8. Continued 
Trait Environment Gene Marker CHR Position MAF A1/A2 








Screen Test Cut-Off 







4.15E-12 8.81E-02 7.63E-07 CO 







4.64E-15 9.12E-02 7.63E-07 CO 







4.63E-09 1.65E-02 7.63E-07 CO 







3.36E-07 1.45E-02 7.63E-07 CO 







6.85E-13 3.56E-02 7.63E-07 CO 







6.15E-10 2.20E-02 7.63E-07 CO 







7.46E-10 4.55E-01 7.63E-07 CO 







6.18E-125 1.16E-02 5.00E-02 CT2 







6.18E-125 1.16E-02 5.00E-02 EDGxE 







2.33E-09 7.71E-02 7.63E-07 CO 







8.17E-11 1.26E-01 7.63E-07 CO 







9.01E-10 4.58E-01 7.63E-07 CO 







3.15E-16 8.06E-03 7.63E-07 CO 







1.99E-09 1.34E-01 7.63E-07 CO 







1.87E-15 9.56E-03 7.63E-07 CO 







1.47E-10 1.43E-01 7.63E-07 CO 







4.69E-09 1.66E-02 7.63E-07 CO 
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Supplemental Table S8. Continued 
Trait Environment Gene Marker CHR Position MAF A1/A2 








Screen Test Cut-Off 







3.15E-09 6.70E-02 7.63E-07 CO 







1.48E-01 7.81E-09 1.16E-11 CC 







1.48E-01 7.81E-09 1.16E-11 EB 







3.48E-11 1.57E-01 1.22E-05 CO 







9.73E-11 1.19E-01 4.88E-05 CO 







8.60E-11 2.09E-02 1.22E-05 CO 







1.87E-12 2.22E-01 4.88E-05 CO 







2.89E-11 3.79E-01 4.88E-05 CO 







2.92E-20 2.65E-02 5.00E-02 EDGxE 







7.47E-13 5.89E-02 1.95E-04 CO 







2.47E-08 3.70E-02 1.22E-05 CO 







5.92E-11 1.39E-01 1.22E-05 CO 







1.97E-14 8.65E-02 3.13E-03 CO 







6.03E-12 1.09E-01 4.88E-05 CO 







2.74E-11 1.56E-01 1.22E-05 CO 







5.97E-12 1.16E-01 4.88E-05 CO 







1.89E-11 4.41E-01 4.88E-05 CO 
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Supplemental Table S8. Continued 
Trait Environment Gene Marker CHR Position MAF A1/A2 








Screen Test Cut-Off 







3.52E-04 1.79E-03 1.91E-07 CO 







7.91E-15 1.58E-03 3.13E-03 CT2 







1.11E-16 1.58E-03 3.13E-03 EDGxE 







3.94E-12 2.06E-01 1.22E-05 CO 







4.87E-17 4.21E-02 4.88E-05 CO 







4.87E-17 4.21E-02 5.00E-02 EDGxE 







4.10E-12 2.07E-01 1.22E-05 CO 







8.32E-12 1.91E-01 3.05E-06 CO 







2.61E-10 1.30E-01 3.05E-06 CO 







2.01E-16 8.90E-02 1.22E-05 CO 







3.50E-10 3.01E-01 3.05E-06 CO 







5.62E-17 4.25E-02 4.88E-05 CO 







6.22E-12 1.11E-01 3.05E-06 CO 







4.75E-12 1.79E-01 3.05E-06 CO 







6.66E-12 1.87E-01 3.05E-06 CO 







3.50E-10 7.48E-03 3.05E-06 CO 







1.14E-11 6.79E-02 3.05E-06 CO 
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Supplemental Table S8. Continued 
Trait Environment Gene Marker CHR Position MAF A1/A2 








Screen Test Cut-Off 







1.60E-14 2.29E-01 1.22E-05 CO 







5.83E-12 1.54E-01 3.05E-06 CO 







6.01E-04 1.11E-02 4.77E-08 CO 







5.66E-12 6.37E-02 3.05E-06 CO 







1.21E-04 2.72E-01 7.63E-07 CO 







8.53E-13 2.09E-01 3.13E-03 CO 







2.66E-08 2.47E-01 5.00E-02 CO 







2.24E-194 2.12E-02 5.00E-02 CT1 







2.24E-194 2.12E-02 5.00E-02 CT2 







6.07E-18 6.47E-03 5.00E-02 EDGxE 







2.86E-20 2.21E-03 5.00E-02 EDGxE 







8.39E-21 1.76E-03 5.00E-02 EDGxE 







1.52E-161 8.95E-03 5.00E-02 CT1 







1.52E-161 8.95E-03 5.00E-02 CT2 







6.18E-125 2.85E-02 5.00E-02 CT1 







6.18E-125 2.85E-02 5.00E-02 CT2 







3.50E-06 5.27E-03 7.81E-04 CO 
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Supplemental Table S8. Continued 
Trait Environment Gene Marker CHR Position MAF A1/A2 








Screen Test Cut-Off 





























7.98E-08 2.33E-02 5.00E-02 CT2 
HBP-S2 
Abdominal Obesity 
Based on WHR 

















Supplemental Table S9. Genomic inflation factors observed in GWISs for hypertension 
Trait Environment 
Marginal Model Gene-by-Environment Interaction Model 
Marginal Main SNP Interactive 
HBP-S1 
Cigarette Smoking 
Ever Smoking 1.048906 1.010773 1.006547 
Current Smoking 1.048906 1.024951 1.014068 
Alcohol Consumption 
Ever Drinking 1.048423 1.017844 0.999534 
Current Drinking 1.048906 1.021156 0.998135 
Moderate Drinking 1.048423 1.038795 1.003270 
Low-Risk Drinking  1.050356* 1.047457 0.990701 
Heavy Drinking  1.050356* 1.044564 0.982845 
Binge Drinking  1.050356* 1.045046 0.935319 
Obesity 
Underweight  1.053261*  1.053746* 0.926015 
Overweight Class 1 1.048906 1.000233 0.971833 
Overweight Class 2 1.049389 1.026377 0.989311 
Obesity  1.057143*  1.060062* 0.962724 
Abdominal Obesity 
Abdominal Obesity Class 1  1.050840* 1.038316 0.990237 
Abdominal Obesity Class 2  1.051324*  1.055201* 1.009363 
Abdominal Obesity Based on WHR  1.050356* 1.019736 1.021156 
* Any inflated results over 1.05 are shown in bold type. 
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Supplemental Table S9. Continued 
Trait Environment 
Marginal Model Gene-by-Environment Interaction Model 
Marginal Main SNP Interactive 
HBP-S2 
Cigarette Smoking 
Ever Smoking 1.037836 1.017844 1.011714 
Current Smoking 1.037836 1.015955 0.997669 
Alcohol Consumption 
Ever Drinking 1.036399 1.018317 1.004205 
Current Drinking 1.036878 1.013126 1.001400 
Moderate Drinking 1.036399 1.026853 0.992091 
Low-Risk Drinking 1.037836 1.033050 1.022578 
Heavy Drinking 1.038316 1.028757 1.034963 
Binge Drinking 1.038795 1.030186 0.985613 
Obesity 
Underweight 1.035920 1.041676 0.933542 
Overweight Class 1 1.036878 0.987923 0.991164 
Overweight Class 2 1.045527 1.010773 1.012655 
Obesity 1.041196 1.041676 1.014068 
Abdominal Obesity 
Abdominal Obesity Class 1 1.037836 1.021630 1.007016 
Abdominal Obesity Class 2 1.039275 1.030186 0.991164 
Abdominal Obesity Based on WHR 1.041676 0.994878 0.969550 
* Any inflated results over 1.05 are shown in bold type. 
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Supplemental Table S10. Effects of the interplay between genes and lifestyle factors on the risk of hypertension 
 
a. Effects of the interplay between DCC and ever smoking on the risk of HBP-S1 
Cigarette Smoking 
Genotype of rs9950661 
TT (95% CI) TC (95% CI) CC (95% CI) 
Normal 1.00 0.97 (0.94-1.01) 0.89 (0.83-0.95) 
Ever Smoking 1.22 (1.17-1.27) 1.13 (1.08-1.18) 1.09 (1.01-1.17) 
Multiplicative Effect 1.22 (1.17-1.27) 1.16 (1.11-1.21) 1.23 (1.12-1.35) 
 
b. Effects of the interplay between RPH3A and low-risk drinking on the risk of HBP-S1 
Alcohol Consumption 
Genotype of rs886476 
AA (95% CI) AG (95% CI) GG (95% CI) 
Normal 1.00 0.98 (0.95-1.01) 0.94 (0.90-0.99) 
Low-Risk Drinking 1.27 (1.19-1.34) 1.11 (1.03-1.20) 1.04 (0.88-1.22) 





Supplemental Table S10. Continued 
 
c. Effects of the interplay between MYL2 and heavy drinking on the risk of HBP-S1 
Alcohol Consumption 
Genotype of rs4766517 
GG (95% CI) GC (95% CI) CC (95% CI) 
Normal 1.00 0.99 (0.95-1.03) 0.97 (0.92-1.01) 
Heavy Drinking 1.14 (1.05-1.24) 1.20 (1.13-1.27) 1.28 (1.20-1.36) 
Multiplicative Effect 1.14 (1.05-1.24) 1.21 (1.14-1.27) 1.33 (1.24-1.42) 
 
d. Effects of the interplay between KLF4 and moderate drinking on the risk of HBP-S1 
Alcohol Consumption 
Genotype of rs79977578 
TT (95% CI) TG (95% CI) GG (95% CI) 
Normal 1.00 1.08 (1.03-1.13) 1.14 (0.93-1.40) 
Moderate Drinking 1.06 (1.02-1.09) 0.87 (0.81-0.93) 1.09 (0.86-1.38) 





Supplemental Table S10. Continued 
 
e. Effects of the interplay between RP11-981P6.1 and obesity on the risk of HBP-S2 
Obesity 
Genotype of rs1689040 
CC (95% CI) CT (95% CI) TT (95% CI) 
Normal 1.00 0.84 (0.79-0.90) 0.80 (0.72-0.88) 
Obese 1.69 (1.44-1.99) 1.84 (1.60-2.11) 1.89 (1.51-2.36) 
Multiplicative Effect 1.69 (1.44-1.99) 2.18 (1.90-2.51) 2.37 (1.87-3.00) 
 
f. Effects of the interplay between ATP2B1 and abdominal obesity class 1 on the risk of HBP-S2 
Abdominal Obesity 
Class 1 
Genotype of rs2681472 
AA (95% CI) AG (95% CI) GG (95% CI) 
Normal 1.00 0.81 (0.74-0.89) 0.76 (0.66-0.87) 
Obese 1.47 (1.35-1.61) 1.32 (1.21-1.44) 1.31 (1.16-1.48) 





Supplemental Table S10. Continued 
 
g. Effects of the interplay between MYL2 and abdominal obesity based on WHR on the risk of HBP-S2 
Abdominal Obesity 
Based on WHR 
Genotype of rs12229654 
TT (95% CI) TG (95% CI) GG (95% CI) 
Normal 1.00 0.87 (0.77-0.98) 0.74 (0.47-1.14) 
Obese 1.78 (1.66-1.91) 1.69 (1.55-1.85) 1.97 (1.59-2.45) 












Supplemental Table S11. Gene-by-obesity interactions on quantitative lipid levels 
Trait Environment Gene Marker CHR Position MAF A1/A2 
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Supplemental Table S11. Continued 
Trait Environment Gene Marker CHR Position MAF A1/A2 
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Supplemental Table S12. Genomic inflation factors observed in GWISs for quantitative TG levels 
Trait Environment 
Marginal Model Gene-by-Environment Interaction Model 
Marginal Main SNP Interactive 
TG 
Obesity 
Overweight Class 1  1.050356* 0.926899 0.955029 
Overweight Class 2 1.047940 1.016899 1.006079 
Obesity 1.041676 1.039275  1.065918* 
Abdominal Obesity 
Abdominal Obesity Class 1 1.045046 1.040715 0.975952 
Abdominal Obesity Class 2 1.041676  1.063475* 0.911091 
Abdominal Obesity Based on WHR 1.044564 0.968182 0.985151 









Supplemental Table S13. Gene-by-lifestyle interactions on quantitative BP levels 
Trait Environment Gene Marker CHR Position MAF A1/A2 


























































































































Supplemental Table S13. Continued 
Trait Environment Gene Marker CHR Position MAF A1/A2 






















































































Supplemental Table S14. Genomic inflation factors observed in GWISs for quantitative SBP levels 
Trait Environment 
Marginal Model Gene-by-Environment Interaction Model 
Marginal Main SNP Interactive 
SBP 
Cigarette Smoking 
Ever Smoking  1.062499*  1.060062* 0.979165 
Current Smoking  1.062987* 1.048906 1.016427 
Alcohol Consumption 
Ever Drinking  1.061524*  1.093064* 1.025902 
Current Drinking  1.062011*  1.093064* 1.007954 
Moderate Drinking  1.061036*  1.079181* 0.943794 
Low-Risk Drinking  1.060549* 1.047940 1.022578 
Heavy Drinking  1.062011* 1.045046 1.014068 
Binge Drinking  1.062987*  1.060062* 0.968182 
Obesity 
Underweight  1.057629*  1.057143*  1.105071* 
Overweight Class 1  1.050840* 0.997204 0.975952 
Overweight Class 2  1.061524* 1.000467 1.034484 
Obesity  1.065918*  1.059089*  1.306686* 
Abdominal Obesity 
Abdominal Obesity Class 1  1.064940* 0.983767 1.037836 
Abdominal Obesity Class 2  1.068365* 1.017844  1.192466* 
Abdominal Obesity Based on WHR  1.064452* 0.929995 0.960003 




Supplemental Figure S1. Analytical models categorized by underlying assumptions and methods for screening (step-1) and hypothesis 
testing (step-2). We categorized analytical approaches for testing GxEs, such as exhaustive scans and two-step methods, by 1) the assumption 




Supplemental Figure S2. Flow chart of inclusion and exclusion criteria for the study on dyslipidemia. We excluded individuals who have 
suffered cancer or diabetes from this study. We considered people taking any kind of lipid-lowering drug as dyslipidemia patients: 1) 95 people 
for the Ansan cohort, 2) 73 people for the Ansung cohort, 3) 83 people for the urban cohort, and 4) 9 people for the rural cohort. (a) Flow chart 











Supplemental Figure S3. Trends of plasma lipid levels stratified into subgroups for obesity traits based on BMI, WC, and WHR. Figure 
(a) shows trends of plasma lipids stratified into subgroups for obesity traits based on BMI: group 1BMI (BMI<18.5 kg/m2), 2BMI (18.5≤BMI<23.0 
kg/m2), 3BMI (23.0≤BMI<25.0 kg/m2), 4BMI (25.0≤BMI<30.0 kg/m2), and 5BMI (30.0 kg/m2≤BMI). Figure (b), on the other hand, described lipid 
trends stratified into subgroups for abdominal obesity traits based on WC or WHR: group 1WC (WC≤90 cm for males, 80 cm for females), 2WC 
(WC>90 cm for males, 80 cm for females), 3WC (WC>102 cm for males, 88 cm for females), and 1WHR (WHR≤0.90 for males, 0.85 for females), 





Supplemental Figure S4. Quantile-Quantile plots for gene-by-obesity interactions on Total-C. We have drawn quantile-quantile plots for 
genetic interactions with obesity traits on the risk of abnormal Total-C elevation. (a) Plots for genetic interactions with BMI. (b) Plots for gene-




















Supplemental Figure S5. Quantile-Quantile plots for gene-by-obesity interactions on HDL-C. We have drawn quantile-quantile plots for 







Supplemental Figure S6. Quantile-Quantile plots for gene-by-obesity interactions on LDL-C. We have drawn quantile-quantile plots for 
genetic interactions with obesity traits on the risk of abnormal LDL-C elevation. (a) Plots for genetic interactions with BMI. (b) Plots for gene-




















Supplemental Figure S7. Quantile-Quantile plots for gene-by-obesity interactions on TG. We illustrated quantile-quantile plots for genetic 
interactions with obesity traits on the risk of abnormal TG elevation. (a) Plots for genetic interactions with BMI. (b) Plots for genetic interactions 




















Supplemental Figure S8. Quantile-Quantile plots for gene-by-obesity interactions on Remnant-C. We have drawn quantile-quantile plots 
for gene-by-obesity interactions on the risk of abnormal elevation of Remnant-C. (a) Plots for genetic interactions with BMI. (b) Plots for gene-




















Supplemental Figure S9. Flow chart of inclusion and exclusion criteria for the study on hypertension. We excluded individuals who have 
suffered cancer or diabetes or any CVDs from this study. We considered people taking any antihypertensive drugs as hypertension patients: 1) 
118 people for the Ansan cohort, 2) 650 people for the Ansung cohort, 3) 376 people for the urban cohort, and 4) 30 people for the rural cohort. 











Supplemental Figure S10. Quantile-Quantile plots for gene-by-lifestyle interactions on HBP-S1. We illustrated quantile-quantile plots for 
genetic interactions with lifestyle factors on the risk of HBP-S1. (a) Plots for genetic interactions with ever smoking on the risk of HBP-S1. (b) 
Plots for genetic interactions with low-risk drinking on the risk of HBP-S1. (c) Plots for genetic interactions with heavy drinking on the risk of 
HBP-S1. (d) Plots for genetic interactions with moderate drinking on the risk of HBP-S1. (e) Plots for genetic interactions with binge drinking 

































Supplemental Figure S11. Quantile-Quantile plots for gene-by-lifestyle interactions on HBP-S2. We illustrated quantile-quantile plots for 
genetic interactions with lifestyle factors on the risk of HBP-S2. (a) Plots for genetic interactions with obesity on the risk of HBP-S2. (b) Plots 
for genetic interactions with abdominal obesity class 1 on the risk of HBP-S2. (c) Plots for genetic interactions with abdominal obesity decided 




















Supplemental Figure S12. Flow chart of inclusion and exclusion criteria for the study on continuous lipid levels. We excluded individuals 
who have suffered cancer or diabetes from this study. We also excluded people taking any kind of lipid-lowering medication: 1) 95 people for 
the Ansan cohort, 2) 73 people for the Ansung cohort, 3) 83 people for the urban cohort, and 4) 9 people for the rural cohort. (a) Flow chart of 











Supplemental Figure S13. Flow chart of inclusion and exclusion criteria for the study on continuous BP levels. We excluded people who 
have suffered cancer or diabetes or CVD from this study. We added 10 mmHg and 5 mmHg to observed SBP and DBP levels, respectively, for 
people taking any antihypertensive drugs: 1) 118 people for the Ansan cohort, 2) 650 people for the Ansung cohort, 3) 376 people for the urban 











Supplemental Figure S14. Quantile-Quantile plots for interactions on quantitative scales of TG and SBP. We illustrated quantile-quantile 
plots for genetic interactions with environmental factors on quantitative scales of outcome variables. (a) Plots for genetic interactions with BMI 
on quantitative TG scales. (b) Plots for genetic interactions with low-risk drinking on quantitative SBP scales. (c) Plots for genetic interactions 





Reference Table R1. Type 1 error rates for GxE tests across several models and methods 
 
Each estimate of type 1 error rate is based on the proportion of 2,000 replicate datasets for which the indicated procedure identified at least one 
statistically significant result among 999,999 non-disease susceptibility variants. aThe base model has no variants with DG associations or EG 
correlations. bNumber of non-disease susceptibility variants simulated to have EG correlations in a source population. cNumber of non-disease 











Reference Table R2. Continued 
Each estimate of power is based on the proportion of 2,000 replicate datasets for which the indicated procedure achieved statistical significance 
for GxEs at the disease susceptibility loci. aEach model varies the indicated parameter from the base model setting. All results are based on the 
sample size of 3,500 cases and 3,500 controls and a total of one million SNPs. The highest estimated power for each analytical model is shown 
in bold type. bThe base model has ORG=1.2, ORE=1.2, ORGxE=1.5, qA=0.23, pE=0.40, initial bin size B=5 SNPs, no associations between disease 
susceptibility loci and environmental factors, no additional SNPs with DG associations or EG correlations. cOR between disease susceptibility 
loci and environmental factors. dNumber of non-disease susceptibility SNPs simulated to have EG correlations in a source population. eNumber 











Reference Figure R1. Power to detect GxEs across a range of magnitudes for the marginal genetic effect for several analytical methods. 
The figures illustrate the statistical power for testing GxEs across a range of marginal genetic effects for several exhaustive scans and two-step 
methods, with 3,500 cases and 3,500 controls. (A) Moderate interaction with common genetic and environmental factors (ORGxE=1.5, qA=0.23, 











Reference Figure R2. True-positive rate to detect GxEs in relation to the disease prevalence, exposure prevalence, and ORGxE for several 
analytical methods. The figures illustrate the true-positive rate to detect interactions in relation to the disease prevalence, exposure prevalence, 
and ORGxE for several exhaustive scans and two-step methods. The alternative hypothesis of a present interaction was simulated for 9,000 SNPs 
at different settings. (A) The number of cases was kept constant to 1,000 individuals; the number of controls was increased from 1,000 to 9,000 
individuals. All other parameters were kept constant (ORGxE=1.5, pE=0.30). (B) The alternative hypothesis was simulated at different exposure 
prevalence. All other parameters were kept constant (n=10,000, ORGxE=1.5). (C) The true-positive rate to detect GxEs was estimated at different 
interactive ORs. All other parameters were kept constant (n=10,000, pE=0.30).
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Abstract in Korean 
 
이상지질혈증 및 고혈압에 대한 전장유전체에서의 




강 문 일 
 
인간의 형질 및 복합질환은 유전적인 요인과 환경적인 요인, 두 요인 간
의 상호작용으로부터 영향을 받는 것으로 알려져 있다. 한국인에게서 가
장 흔한 만성질환임에도 불구하고, 지금까지 한국인을 대상으로 한 이상
지질혈증 및 고혈압에 대한 유전자-환경 상호작용 연구는 활발하게 이루
어지지 않았다. 유럽계 인종을 중심으로 한 대규모의 전장유전체 연구로
부터 지질 및 혈압과 연관된 유전변이가 각각 500개, 800개 이상 발견되
었음에도 불구하고, 이를 통해 설명할 수 있는 각 형질의 유전율은 기대
보다 낮았다. 따라서 본 연구는 한국인의 역학자료를 사용하여 이상지질
혈증 및 고혈압과 연관되어 있는 유전자-환경 상호작용을 전장유전체 수
준에서 검정하고, 이를 통해 추가적으로 설명할 수 있는 각 형질의 유전
율을 제시하는 것을 목표로 한다. 유전요인과 환경요인 간의 상호작용을 
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연구함으로써 이상지질혈증 및 고혈압과 같은 복합질환의 생물학적인 기
전을 이해하고, 더 나은 예측모형을 개발할 수 있을 것이라 기대한다. 
 
이상지질혈증 및 고혈압에 대한 전장유전체에서의 유전자-환경 상호작용 
연구를 수행하기 위하여 한국인유전체역학조사사업으로부터 총 18,025명
의 대상자를 선별하였다. 이상지질혈증 및 고혈압은 각 질환의 임상진료
지침에 제시된 진단기준에 따라 정의하였고, 흡연 및 음주, 비만과 같은 
환경요인 또한 일반적으로 사용되고 있는 기준에 따라 정의하였다. 유전
요인의 경우, 총 3,914,038개의 단일염기다형성에 대하여 각각의 유전자
-환경 상호작용을 검정하였으며, 이를 위해 현재까지 개발된 분석모형을 
최대한 다양하게 적용하였다. 모든 분석 결과는 지역사회기반코호트로부
터 검정된 이후에 도시 및 농촌기반코호트를 통해 재확인되었으며, 최종
적으로 확인된 유전자-환경 상호작용을 통하여 추가적으로 설명할 수 있
는 각 형질의 유전율을 제시하였다. 이러한 연구 결과를 지질 및 혈압에 
대한 유전자-환경 상호작용 연구 결과와 비교하여 제시하였다. 
 
이상지질혈증에 대한 유전자-환경 상호작용 연구를 통하여 약 20개의 유
전자-비만 상호작용을 확인하였다. 본 연구의 결과는 두 개의 새로운 유
전자(SCN1A, SLC12A8)와 기존의 전장유전체 연구로부터 지질과 연관된 
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것으로 보고되었던 유전자(APOA5, BUD13, ZNF259, HMGCR)를 포함한
다. 또한 새롭게 발견된 유전자-비만 상호작용을 통하여 각 지질의 유전
율을 추가적으로 설명하였다. 중성지방의 경우, 유전자-비만 상호작용을 
통하여 18.7%의 유전율을 추가적으로 설명할 수 있었다. 고혈압에 대한 
유전요인과 환경요인 간의 상호작용 연구를 통하여 총 24개의 유전자-환
경 상호작용을 확인하였다. 본 연구의 결과는 지금까지 보고되지 않았던 
두 개의 유전자(BRAP, SH2B3), 혈압 및 비만과 연관된 유전자(ATP2B1, 
ST5), 그리고 기존의 전장유전체 연구로부터 음주와 연관된 것으로 보고
되었던 유전자(ALDH2, CUX2, HECTD4, MYL2, OAS3)를 포함한다. 이러
한 유전자-환경 상호작용을 고려할 경우, 약 0.3-2.1%의 유전율이 추가
적으로 설명되는 것을 확인하였다. 지질 및 혈압에 대한 유전자-환경 상
호작용 연구를 통하여 APOA5, BUD13에 위치한 네 개의 유전변이가 비
만요인과의 상호작용을 통하여 중성지방에 영향을 준다는 것을 확인하였
고, TSPAN5에 위치한 유전변이가 음주요인과 상호작용을 하여 수축기혈
압에 영향을 준다는 것을 확인하였다. 
 
본 연구를 통하여 특정한 유전요인을 가진 인구집단의 경우에는 흡연 및 
음주, 비만요인이 정상적인 범주에 속함에도 불구하고, 이상지질혈증 및 
고혈압 발생에 취약할 수 있다는 것을 확인하였다. 또한 유전자-환경 상
호작용을 통하여 각 형질의 유전율을 추가적으로 설명할 수 있다는 것과 
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유전자-환경 상호작용과 연관된 단일염기다형성의 빈도가 인종별로 다르
게 나타나는 것으로부터 각 인종별로 이상지질혈증 및 고혈압의 발생 위
험도가 다를 수 있다는 것을 확인하였다. 본 연구를 통하여 새롭게 확인
된 유전자-환경 상호작용은 인구집단을 각 질환의 고위험군 및 저위험군
으로 구별하여 각 위험군에 특화된 임상진료지침을 제시하거나 맞춤의학 
및 정밀의료를 실현하기 위한 하나의 근거로 사용될 수 있을 것이다. 
 
주요어: 이상지질혈증, 고혈압, 흡연, 음주, 비만, 전장유전체, 유전자-
환경 상호작용, 유전율, 메타분석 
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